2015N232375_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 201810
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A multi -center, randomized, double-blind, placebo controlled, 
parallel group stud y to compare cessation versus continuation of 
long-term mepolizumab treatment in patients with severe 
eosinophilic asthma (201810)
Compound Number: SB-240563
Development Phase: IIIB
Effective Date: 07-JUL-2016
Protocol Amendment Number:   02
Author (s):  
Copy right [ADDRESS_738332] dose
2. Corrected s ymptom score from ≥5 to 5
3. Language allows for inflammatory  biomarkers to be tested at [COMPANY_004] 
4. eDiary  arrow adjusted to span from Visit B2 to the Exit Visit or EW/I P DISC
5. Estradiol, FSH, drug alcohol screens onl y conducted if clinicall y indicated
6. Added further explanation of Part D switch during a visit
7. Extended Part A to 2.5 years in text and Table 6
8. In Section 7.9.2, added a statement that recreational drug us is not allowed during 
the study
9. In Table 7, added a line for biomarker anal ysis
10. Added clarify ing langua ge to the disallowance of treatment gaps during 201312 
and MEA115666
2015N232375_02 2015 -NOV -06 Amendment No. 1
1. Change of Secondary  Medical Monitor
2. Simplified definition of “continuous mepolizumab treatment”
3. Clarified when a subject switches from Part C to Part D
4. Removed the process of withdrawing a subject due to unblinding
5. Several minor changes to the Time and Events table and corresponding text 
within the protocol to ensure subjects entering from MEA115666 and 201312 are 
consistently  and correctly  moni tored
6. Removed Urinal ysis testing
7. Updated contraception requirements
2015N232375_03 2016 -JUL-07 Amendment No. 2
1. Amended Section 5.6.1 Risk Assessment
2. Corrected numbering of Exclusion Criteria
3. Amended exclusion criterion No. 7 in Section 6.2: Exclusion Criteria
4. Amended Randomization Exclusion criterion No. 7 in Section 6.3.2: 
Randomization Exclusion Criteria.
5. Additional text added to Section 7.[ADDRESS_738333] and Other Study  
Treatment 
6. Amended Section 7.9.1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
7. Multiple changes to Section 7.9.2 Prohibited Medications and Non -Drug 
Therapi[INVESTIGATOR_014]
8. Removed interactive response technology  requirements from certain visits of the 
T&E tables
9. Added Phy sical Examination at Visit C1 in Time and Events table 
10. Added Phy sical Examination to C1 visit
2015N232375_03 CONFIDENTIA L
The GlaxoSmithKline group of companies [ADDRESS_738334]/Clinician Rating of Global Impression of Disease Severity and 
Response to Therap y
12. Clarified unblinding risk when performing local laboratory  testing
13. Updated biomarker collection text
14. Removed “Xolair” from the T rademark Information section
.
[COMPANY_003]
[COMPANY_003]
2015N232375_03 CONFIDENTI AL
201810
5MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_132025] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite 
Address
Primary 
Medical 
Monitor  
 MD, 
MFPMNot 
ApplicableStockley 
Park 
West
1-[ADDRESS_738335]  
information Medical 
monitor as 
above
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_738336]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_561909]
2015N232375_03 CONFIDENTI AL
201810
6person in the territory  will be provided to the relevant regulatory  authority  as part of the 
clinical trial application.   
Regulatory  Agency  Identify ing Number(s): IND No. 006971, EudraCT No: [ADDRESS_738337] igator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2015N232375_03 CONFIDENTI AL
201810
8TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 201810 ................................ ...................... 12
2.INTRODUCTION ................................ ................................ ................................ ....18
2.1. Study Rationale ................................ ................................ .......................... 18
2.2. Brief Background ................................ ................................ ........................ 18
3.OBJECTIVES ................................ ................................ ................................ ......... 19
3.1. Primary Objective ................................ ................................ ....................... 19
3.2. Secondary Objective ................................ ................................ ................... 19
4.ENDPOINTS ................................ ................................ ................................ .......... 19
5.STUDY DESIGN ................................ ................................ ................................ ....21
5.1. Overall Design ................................ ................................ ............................ 21
5.2. Study Phases, Duration and Treatment Arms ................................ ............. 24
5.3. Type and Number of Subjects ................................ ................................ .....25
5.4. Design Justification ................................ ................................ ..................... 26
5.5. Dose Justification ................................ ................................ ........................ 27
5.6. Benefit:Risk Assessment ................................ ................................ ............ 27
5.6.1. Risk Assessment ................................ ................................ ......... 27
5.6.2. Benefit Assessment ................................ ................................ .....34
5.6.3. Overall Benefit:Risk Conclusion ................................ ................... 34
6.SELECTION OF STUDY P OPULATION, IP DISCON TINUATION AN D 
WITHDRAW AL CRITERIA ................................ ................................ ..................... 34
6.1. Inclusion Criteria ................................ ................................ ......................... 35
6.2. Exclusion Cr iteria ................................ ................................ ........................ 36
6.3. Randomization Criteria ................................ ................................ ............... 37
6.3.1. Randomization Inclusion Criteria ................................ ................. 37
6.3.2. Randomization Exclusion Criteria ................................ ................ 37
6.4. Pre-screen/Screen/Run -in Failures ................................ ............................. 38
6.5. Study W ithdrawal Prior to Randomiz ation: Withdrawal during Part A 
or Part B ................................ ................................ ................................ .....[ADDRESS_738338] (IP) during Part C or Part 
D................................ ................................ ................................ ................. [ADDRESS_738339] and Other Study Treatment ................................ ....43
7.2. Treatment Assignment ................................ ................................ ................ 44
7.3. Blinding ................................ ................................ ................................ .......44
2015N232375_03 CONFIDENTI AL
201810
97.4. Packaging and Labeling ................................ ................................ .............. 45
7.5. Preparation/Handling/Storage/Accountability ................................ .............. 45
7.6. Compliance with Study Treatment Administration ................................ .......46
7.7. Treatment of Study Treatment Overdose ................................ .................... 46
7.8. Treatment after the End of the Study ................................ .......................... 46
7.9. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] ................................ ....47
7.9.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 47
7.9.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 47
8.STUDY ASSESSMENTS AN D PROCEDURES ................................ ..................... 48
8.1. Time and Events Tables ................................ ................................ ............. 49
8.2. Screening and Critical Baseline Assessments ................................ ............ 57
8.2.1. Critical procedures performed at Screening (Visit 1) .................... 57
8.2.2. Critical procedures performed at entry to Part B (Visit B1) ........... 58
8.2.3. Critical procedures performed at Randomization (Visit C1) .......... 58
8.3. Efficacy ................................ ................................ ................................ .......59
8.3.1. Efficacy Endpoints ................................ ................................ .......59
8.3.2. Efficacy Assessments ................................ ................................ ..59
[IP_ADDRESS]. Asthma Exacerbations ................................ ................ 59
[IP_ADDRESS].1. Guideline for Assessing Multiple 
Exacerbations ................................ ......... 60
[IP_ADDRESS]. eDiary Reporting, Worsening of Asthma and 
Alerts: Part B, C and D ................................ ............... 60
[IP_ADDRESS].1. eDiary Alerts Indicating W orsening 
of Asthma ................................ ............... 60
[IP_ADDRESS].2. eDiary Daily Entry: Missed Days 
of Work or School ................................ ...60
[IP_ADDRESS].3. eDiary W eekly Entry: Asthma 
Control Questionnaire -5 (ACQ -5)............ 61
[IP_ADDRESS].4. eDiary Compliance ................................ .61
[IP_ADDRESS]. Paper Diary ................................ ................................ 61
[IP_ADDRESS]. Spi[INVESTIGATOR_038] ................................ ................................ ..61
[IP_ADDRESS].1. Pre-and Post -
Albuterol/Salbutamol Spi[INVESTIGATOR_038] ............ 62
[IP_ADDRESS]. Paper -based Asthma Control Questionnaire -5 
(Part A only) ................................ ............................... 62
[IP_ADDRESS]. St. Ge orge’s Respi[INVESTIGATOR_6015] 
(SGRQ) ................................ ................................ ......62
[IP_ADDRESS]. Subject/Clinician Rating of Global Impression 
of Disease Severity and Response to Therapy ........... 62
[IP_ADDRESS]. Healthcare Resource Utilization ................................ ..63
8.4. Safety ................................ ................................ ................................ ......... 63
8.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 63
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................ ................... 64
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 64
[IP_ADDRESS]. Follow -up of AEs and SAEs ................................ ........ 65
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 65
[IP_ADDRESS].1. Cardiovascular Events ............................ 65
[IP_ADDRESS].2. Death Events ................................ .......... 65
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 65
8.4.2. Pregnancy ................................ ................................ ................... 66
2015N232375_03 CONFIDENTI AL
201810
108.4.3. Physical Exams ................................ ................................ ........... 66
8.4.4. Vital Signs ................................ ................................ .................... 66
8.4.5. Electrocardiogram (ECG) ................................ ............................. 66
8.4.6. Clinical Safety Laboratory Assessments ................................ ......67
[IP_ADDRESS]. Immunogenicity ................................ .......................... 69
8.5. Biomarker(s)/Pharmacodynamic Markers ................................ ................... 69
8.6. Genetics ................................ ................................ ................................ .....69
9.DATA MANAGEMENT ................................ ................................ ........................... 69
10.STATISTICAL CONSIDER ATIONS AND DATA ANAL YSES ................................ .70
10.1. Hypotheses ................................ ................................ ................................ .70
10.2. Sample Size Considerations ................................ ................................ .......70
10.2.1. Sample Size Assumptions ................................ ........................... 70
10.2.2. Sample Size Sensitivity ................................ ................................ 70
10.2.3. Sample Size Re -estimation or Adjustment ................................ ...71
10.3. Data Analysis Considerations ................................ ................................ .....71
10.3.1. Analysis Populations ................................ ................................ ....71
10.3.2. Interim Analysis ................................ ................................ ........... 72
10.4. Key Elements of Analysis Plan ................................ ................................ ...72
10.4.1. Primary Analyses ................................ ................................ ......... 72
10.4.2. Secondary Analyses ................................ ................................ ....72
10.4.3. Other Analyses ................................ ................................ ............ 73
[IP_ADDRESS]. Efficacy Analyses ................................ ....................... 73
[IP_ADDRESS]. Safety Analyses ................................ .......................... 73
[IP_ADDRESS].1. Extent of Exposure ................................ .73
[IP_ADDRESS].2. Adverse Events ................................ ......73
[IP_ADDRESS].3. Clinical Laboratory Evaluations ............... 73
[IP_ADDRESS].4. Other Safety Measures ........................... 73
[IP_ADDRESS].5. Immunogenicity ................................ ......73
[IP_ADDRESS]. Pharmacogenetic Analyses ................................ ........ 74
11.STUDY GOVERNANCE CON SIDERATIONS ................................ ........................ 74
11.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 74
11.2. Regulatory an d Ethical Considerations, Including the Informed 
Consent Process ................................ ................................ ........................ 74
11.3. Quality Control (Study Monitoring) ................................ .............................. 75
11.4. Quality Assurance ................................ ................................ ....................... 75
11.5. Study and Site Closure ................................ ................................ ............... 75
11.6. Records Retention ................................ ................................ ...................... 76
11.7. Provision of Study Results to Investigators, Posting of Informati on 
on Publically Available Clinical Trials Registers and Publication ................. 77
12.REFERENCES ................................ ................................ ................................ .......78
13.APPENDICES ................................ ................................ ................................ ........ 81
13.1. Appendix 1: Abbreviations and Trademarks ................................ ................ 81
13.2. Appendix 2: Liver Chemistry Stoppi[INVESTIGATOR_424271] ................................ ................................ ................................ ....84
13.3. Appendix 3: Liver Safety Required Actions and Follow up 
Assessments ................................ ................................ .............................. 86
2015N232375_03 CONFIDENTI AL
[PHONE_11661].4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Ad verse Events ................................ ............... 90
13.4.1. Definition of Adverse Events ................................ ........................ 90
13.4.2. Defin ition of Serious Adverse Events ................................ ........... 91
13.4.3. Definition of Cardiovascular Events ................................ ............. 92
13.4.4. Recording of AEs and SAEs ................................ ........................ 93
13.4.5. Evaluating AEs and SAEs ................................ ............................ 94
13.4.6. Reporting of SAEs to [COMPANY_004] ................................ ........................... 95
13.5. Appendix 5: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) and 
Collection of Pregnancy Information ................................ ........................... 96
13.5.1. Collection of Pregnancy Information ................................ ............ 96
13.6. Appendix 6: Cardiovascular Screening Questions ................................ ......98
13.7. Appendix 7: Daily Asthma Symptom Sc ore................................ ................. 99
13.8. Appendix 8: Anaphylaxis Criteria ................................ .............................. 100
13.9. Appendix 9: C ountry Specific Requirements ................................ ............. 101
13.10. Appendix 10: Protocol Amendment Changes ................................ ............ 102
13.10.1. Amendment 01 (06 -Nov-2015) from the Original Protocol 
(23-Jun-2015) ................................ ................................ ............ 102
13.10.2. Amendment 2 (07 -JUL-2016) from the Amendment 1 (06-
NOV -2015) ................................ ................................ ................ 136
2015N232375_03 CONFIDENTI AL
201810
121. PROTOCOL SYNOPSIS FOR STUDY 201810
Rationale
The efficacy  of mepolizumab in severe asthma has been demonstrated over one y ear of 
continuous treatment in double -blinded studies. However, it is currentl y unknown 
whether chronic exposure is necessary  for disease control. I t was recentl y reported that 
discontinuation of mepolizumab after one year of treatment resulted in the increased 
presence of eosinophils and a corresponding increase in exacerbation frequency  to pre -
study  levels, suggesting that a treatment response was not sustained after treatment 
discontinuation. Bey ond one y ear of treatment, there is no data available on the 
sustainability  of a treatment response following the discontinuation of mepolizumab.
Asthma management guidelines recommend steppi[INVESTIGATOR_561871] y once control is 
achieved in an effort to find the patient’s minimal effective treatment. Thus, it remains 
important to unders tand the duration of response to mepolizumab when treatment is 
withdrawn after longer -term exposure.
Objectives
Primary  Objective
To evaluate whether patients with severe eosinophilic asthma who have received long -
term treatment with mepolizumab (at least 3 y ears) need to maintain treatment with 
mepolizumab to continue to receive benefit. 
Secondary  Objective
To assess the safet y and tolerabilit y of mepolizumab continuation compared to placebo 
following long -term treatment with mepolizumab in patients with severe eosinophilic 
asthma .
Endpoints
Primary  Endpoint
Time to first clinically  significant exacerbation
Clinically  significant exacerbations will be defined as worsening of asthma which 
requires use of s ystemic corticosteroids1and/or hospi[INVESTIGATOR_561872]/or emergency  
department (ED) visits.
1For all subjects, i.v. or oral cortico steroid (e.g., prednisone) for at least 3 days 
or a single intramu scular (IM) corticosteroid dose is required. For subjects on 
maintenance systemic corticosteroids, at least double the existing maintenance 
dose for at least 3 days is required. 
2015N232375_03 CONFIDENTI AL
201810
13Secondary  Endpoints
Ratio to baseline in blood eosinophil count at weeks 12, 24, 36 and 52
Time to a decrease in asthma control, defined as an increase from baseline in 
Asthma Control Questionnaire -5 (ACQ -5) score of ≥ 0.5 units
Time to first exacerbation requir ing hospi[INVESTIGATOR_561873]
Time to first exacerbation requiring hospi[INVESTIGATOR_059] 
Mean change from baseline in clinic pre -bronchodilator FEV 1 atweeks 12, 24, 
36, 52
Mean change from baseline in clinic post -bronchodilator FEV 1at weeks 12, 24, 
36, 52
Mean change from baseline in dail y salbutamol/albuterol use
Mean change from baseline in daily  asthma sy mptom scores 
Mean change from baseline in awakening at night due to asthma sy mptoms 
requiring rescue medication use
Mean change from baseline in morning (AM) Peak Expi[INVESTIGATOR_105177] (PEF)
Time to worsening of asthma (subjects meeting at least [ADDRESS_738340] 2 consecutive day s)
AM PEF: Decrease in AM PEF 30% compared with baseline (last 7 
days of run -inPart B ).
Rescue Medication Use: Anincrease of 50% in rescue medication 
compared with the average use for the previous week.
Night time awakenings requiring rescue medication: Awakening 
due to asthma sy mptoms requiring rescue medication
Symptoms: An asthma symptom score of 5
Mean change from baseline in ACQ -5 score 
Proportion of patients experiencing a decrease in asthma control, defined as an 
increase from baseline in ACQ -5 score of ≥0.5 or more units 
 Proportion of subjects with a clinically  meaningful worsening of health -related 
quality of life measurements (St. George’s Respi[INVESTIGATOR_6015] , SGRQ) at 
weeks 12, 24, 36 and 52 (defined as subjects who have a clinically  relevant 
increase from baseline of ≥4 units in SGRQ score).
Mean change from baseline in SGRQ score at week 12, 24, 36 and 52
Subject/Clinician global impression of asthma severity  rating at weeks 12, 24, 
36 and 52
2015N232375_03 CONFIDENTI AL
201810
14Subject/Clinician  rating of response to therap y at weeks 12, 24, 36 and 52
Number of day s in hospi[INVESTIGATOR_561874]
Unscheduled healthcare contacts/resour ce utilisation
Days off of regular work/school
Safety  Endpoints
Adverse Events and Serious Adverse Events
Clinical L aboratory  parameters
12-lead ECG parameters
Vital Signs
Overall Design
This is a 52 -week, 2 -arm, randomized, double -blind, parallel -group, multi -center study  
evaluating mepolizumab 100 mg and placebo administered subcutaneousl y (SC) every  [ADDRESS_738341] 
no treatment gaps of more than 12 weeks (84 day s) between any  two doses of 
mepolizumab in MEA 115666 or 201312 , will be eligible to participate in this study . 
It is intended that the Follow up/Exit Visit or Early  Withdrawal (EW) Visit for studies 
MEA115666 and 201312 will serve as the Pre -Screening/Screening Visit (Visit 0/Visit 1) 
for this study .
Part A and B: Variable and Fixed Open -Label Run -In Periods
At Visit 1 (Screening), eligible subjects will have their exposure period for mepolizumab 
treatment assessed:
Subjects with less than 3 years of mepolizumab treatment will enter Part A of 
the stud y, a variable open -label run -in period on mepolizumab (100 mg SC every  
4 weeks) of [ADDRESS_738342] will enter Part B 
of the study  at Visit B1 and complete a fixed run -in period of 4 weeks (up 
to 8 weeks) during which open -label mepolizumab (100 mg SC every  4 
weeks) is administered, in order to collect baseline information.
2015N232375_03 CONFIDENTI AL
201810
15Subjects with at least 3years of mepolizumab treatment will directl y enter 
Part B of the stud y. For these subjects, assessments for Visit 1 and Visit B1 
should be conducted on the same day . No assessments should be duplicated.
Part C: Double -Blind Treatment Period
Upon completion of the fixed run -in period Part B, eligible subjects will be randomized 
1:1 to the following double -blinded treatment arms at Visit C1:
mepolizumab (100 mg) administered SC every  4 weeks
placebo administered SC every  4 weeks 
Part D: Optional Switch to Open -Label Mepolizumab
Subjects who ex perience a clinically significant asthma exacerbation during the double -
blind treatment period Part C will require a prompt assessment by  [CONTACT_561910] -blind study  treatment. 
Subjects deemed to be unsu itable to continue double -blind study  treatment by  [CONTACT_561911] -blind investigational product (I P) and complete a 
Discontinuation of I P Visit approximately  [ADDRESS_738343] -randomization. 
No assessments should be duplicated.
Switch to Part D between visits: For example, if a subject completed Visit C7 at Week 24 
(and the subject received a dose of IP at Visit C7) and it is later determined that they  
should switch to Part D, the I P Discontinuation assessments and the first visit in Part D 
will be D8 at Week 28. 
Switch to Pa rt D during a visit: If a subject is in the process of completing a Part C visit, 
as long as they  have not y et received a dose of IP, they  may  be switched to Part D at that 
same visit (e.g., a subject that is part way  through Visit C7 at Week [ADDRESS_738344] 
dose of IP was at Visit C6, Week 20 can be switched to Part D and complete the I P 
Discontinuation assessments and Visit D7 at that same visit, Week 24). 
An Exit Visit will be conducted 52 weeks after randomization (whether the subject is in 
Part C or Part D) in order to assess subject’s efficacy  parameters, immunogenicity  status, 
and to conduct additional safet y assessments. 
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . If a subject discontinues double blind study  
treatment during Part C and does not switch to Part D at their next visit (I P 
2015N232375_03 CONFIDENTI AL
201810
16Discontinuation Visit) after experiencing a clinically  significant asthma exacerbation, the 
subject cannot enter Part D at a later v isit.  
Treatment A rms and Duration
Eligible subjects will participate in the study  ranging from 56 to1 92weeks , depending on 
the duration of Part A (0 to 132weeks) and Part B (4 to 8 weeks). A summary  of study  
phases is described in Table 1.
Table 1 Study  Phases, Duration and Study  Treatments
Study 
PhasePhase Title Duration Treatment arms
Part A Variable 
Open -Label 
Run-in0 to 132
weeksOpen-label mepolizumab (100 mg SC) 
every  4 weeks
Part B Fixed Open -
Label Run -In4 weeks (up 
to 8 weeks)Open -label mepolizumab (100 mg SC) 
every  4 weeks
Part C Double Blind 
Treatment 
Period52 weeks Subjects randomized 1:1 to double -blind 
study  treatment:
mepolizumab (100 mg SC) every  4 
weeks
placebo administered SC every  [ADDRESS_738345] -
randomizationOpen -label mepolizumab (100 mg SC) 
every  4 weeks
Type and Number of Subjects
Subjects with severe eosinophilic asthma who completed the Follow Up/Exit Visit or EW 
Visit from either open -label study  MEA115666 or 201312 will be eligible to participate 
in this study .
Approximately  375 subjects from studies MEA115666 and 201312 are expected to be 
screened in order for approximately  300 subjects to be randomized 1:1 to double -blind 
study  treatment (150 per arm). 
2015N232375_03 CONFIDENTI AL
201810
17Sample Size and Anal ysis
With a sample size of 300 randomized subjects (150 per arm), it is estimated that 
statistical significance wil l be declared if the proportion of subjects with a clinically  
significant exacerbation following withdrawal of mepolizumab is 52.5% compared to 
40% for those continuing to receive mepolizumab (hazard ratio = 0.686).
If the true hazard ratio is 0.55 (corres ponding to a proportion with a clinically  significant 
exacerbation following discontinuation of mepolizumab of 60.5%), then the study  has a 
probability  of 90% of observing a hazard ratio of < 0.686 and therefore the study  has 
90% power for declaring statis tical significance on this endpoint. 
Time to first clinically  significant exacerbation will be compared between treatment 
groups using a Cox’s proportional hazards model allowing for covariates of region, 
exacerbations in the year prior to randomi zation and use of baseline maintenance oral 
corticosteroids (OCS vs no OCS) .
2015N232375_03 CONFIDENTI AL
[ADDRESS_738346] s specifically  play s a central role in the 
pathogenesis of asthma [ Cohn , 2004].  Eosinophils are not normall y present in healthy  
lungs, and are thought to play  a major role in maintaining airway  inflammation [ Walsh ; 
2010; Wadsworth ,2011].  Studies inthe severe asthma population have shown that more 
than half of these patients have persistent eosinop hilic (>3% eosinophils) airway  
inflammation despi[INVESTIGATOR_561875] y [Wenzel , 2005; ENFUMOSA , 2003].
Of the inflammatory  mediators postulated to contribute to the regulation of eosinophil 
trafficking and degranulation, interleukin -5 (IL-5)hasbeen identified as the main 
cytokine to selectivel y regulate eosinophil function [Sumitas , 2011]. IL-5 specificall y 
promotes the differentiation of eosinophils in the bone marrow and stimulates the release 
of eosinophils from the bone marrow into peripheral circulation [Sanderson , 1992; 
Collins , 1995] . Binding of IL -5 to eosinophil -express ingIL-5 receptors results in 
enhanced adhesion of eosinophils to endothelial cells and incre ased eosinophil survival 
and activation [Lopez, 1988] .
Mepolizumab is a humanized anti -interleukin 5 (anti -IL5) antibod y (IgG Kappa) that 
binds to and inactivates IL -5. Mepolizumab is currently  under clinical development for 
the treatment of severe asthma .
2.1. Stud y Rationale
The efficacy  of mepolizumab in severe asthma has been demonstrated over one y ear of 
continuous treatmen t in double -blinded studies. However, it is currentl y unknown 
whether chronic exposure is necessary  for disease control. I t was recentl y reported that 
discontinuation of mepolizumab after one year of treatment resulted in the increased 
presence of eosinoph ils and a corresponding increase in exacerbation frequency  to pre -
study  levels, suggesting that a treatment response was not sustained after treatment 
discontinuation [ Haldar , 2014].  Bey ond one y ear of treatment, there is no data available 
on the sustainability  of a treatment response following the discontinuation of 
mepolizumab.
Asthma management guidelines recommend steppi[INVESTIGATOR_561871] y once control is 
achieved in an eff ort to find the patient’s minimal effective treatment [GINA, 2015 ].
Thus, it remains important to understand the duration of response to mepolizumab when 
treatment is withdrawn after longer -term exposure.
2.2. Brief Background
Mepolizumab binds with high affinity  to human IL-5 and blocks its binding to and the 
activation of t he IL -5 receptor (CD125).
The randomi zed, multi -centre , placebo -controlled exacerbation s tudies (MEA112997, 
MEA115588) and Oral Corticosteroid ( OCS )Reduction Study  (MEA115575 ) have 
demonstrate dthe efficacy  of mepolizumab and support the use of mepolizuma b 100 mg 
2015N232375_03 CONFIDENTI AL
201810
19SC every  4 weeks as an add -on therap y for the treatment of severe eosinophilic asthma.
Compared with placebo, mepolizumab has been shown to: 
Reduce the rate of clinically  significant exacerbations by  [CONTACT_3450]  50%.  These 
results were replica ted in studies MEA112997 and MEA115588.
Reduce the rate of exacerbations requiring hospi[INVESTIGATOR_131954]/or Emergency 
Department ( ED)visits ,with mean reductions ranging from 32% to 61%.
Produce statistically  significant and/or clinicall y relevant improvem ents in lung 
function based on forced expi[INVESTIGATOR_131955] (FEV 1), asthma control 
based on Asthma Control Questionnaire (ACQ -5), quality  of life based on St. 
George’s Respi[INVESTIGATOR_21606] (SGRQ) and clinician and subject -rated overall 
respo nse to therapy  in the target population.  
Produce consistent reductions in blood eosinophil levels detected at Week 4 which 
were sustained for the duration of treatment.
Additional d etails of the pharmacology , efficacy  and safet y can be foun d in the 
Inves tigator Brochure (IB) .
3. OBJECTIVE S
3.1. Primary  Objective
To evaluate whether patients with severe eosinophilic asthma who have received long -
term treatment with mepolizumab (at least 3 y ears) need to maintain treatment with 
mepolizumab to continue to receive benefit. 
3.2. Secondary  Objective
To assess the safet y and tolerabilit y of mepolizumab continuation compared to placebo 
following long -term treatment with mepolizumab in patients with severe eosinophilic 
asthma .
4. ENDPOINT S
Primary  Endpoint
Time to first clinically  significant exacerbation
Clinically  significant e xacerbations will be defined as worsening of asthma which 
requires use of s ystemic corticosteroids1and/or hospi[INVESTIGATOR_561872]/or ED visits.
1For all subjects, i.v. or oral cortico steroid (e.g., prednisone) for at least 3 days 
or a single intramuscular (IM) corticoster oiddose is required. For subjects on 
maintenance systemic corticosteroids, at least double the existing maintenance 
dose for at least 3 days is required. 
2015N232375_03 CONFIDENTI AL
201810
20Secondary  Endpoints
Ratio to baseline in blood eosinophil count at weeks 12, 24, 36 and 52
Time to a decrease in asthma control, defined as an increase from baseline in 
Asthma Control Questionnaire -5 (ACQ -5) score of ≥ 0.5 units
Time to first exacerbation requir ing hospi[INVESTIGATOR_561873]
Time to first exacerbation requiring hospi[INVESTIGATOR_059] 
Mean change from baseline in clinic pre -bronchodilator FEV 1 atweeks 12, 24, 
36, 52
Mean change from baseline in clinic post -bronchodilator FEV 1at weeks 12, 24, 
36, 52
Mean change from baseline in dail y salbutamol/albuterol use
Mean change from baseline in daily  asthma sy mptom scores 
Mean change from baseline in awakening at night due to asthma sy mptoms 
requiring rescue medication use
Mean change from baseline in morning (AM) Peak Expi[INVESTIGATOR_105177] ( PEF)
Time to worsening of asthma (subjects meeting at least [ADDRESS_738347] 2 consecutive day s)
AM PEF: Decrease in AM PEF 30% compared with baseline (last 7 
days of run -inPart B)
Rescue Medication Use: An increase of 50% in rescue medication 
compared with the av erage use for the previous week
Night time awakenings requiring rescue medication: Awakening 
due to asthma sy mptoms requiring rescue medication
Symptoms: An asthma symptom score of 5
Mean change from baseline in ACQ -5 score 
Proportion of patients experiencing a decrease in asthma control, defined as an 
increase from baseline in ACQ -5 score of ≥ 0.5 units 
Proportion of subjects with a clinically  meaningful worsening of health -related 
quality  of life measurements ( SGRQ) at weeks 12, 24, 36 and 52 (defined as 
subjects who have a clinically  relevant increase from baseline of ≥4 units in 
SGRQ score).
Mean change from baseline in SGRQ score at week 12, 24, 36 and 52
Subject/Clinician global impression of asthma severity  rating at weeks 12, 24, 
36 and 52
2015N232375_03 CONFIDENTI AL
201810
21Subject/Clinician  rating of response to therap y at weeks 12, 24, 36 and 52
Number of day s in hospi[INVESTIGATOR_561874]
Unscheduled healthcare contacts/resource utilisation
Days off of regular work/school
Safety  Endpoints
Adverse Events and Serious Adverse Events
Clinical L aboratory  parameters
12-lead ECG parameters
Vital Signs
5. STUDY DESIGN
5.1. Overall Design
This is a [ADDRESS_738348] 3 y ears.
Definition of Continuous Mepolizumab Treatment 
Continuous treatment with mepolizumab is defined as no more than 2 consecutive missed 
doses, i.e. no treatment gaps of more than 12 weeks (84 day s) between an y two doses. 
When deriving the period of continuous mepolizumab exposure, treatment f rom the 
following studies may  be considered: MEA115666, MEA115588, MEA115575, 
MEA115661 and 201312. The earliest date of initiating mepolizumab treatment may  be 
considered when deriving this total exposure, however if a gap of >84 days between an y 
two dose s of mepolizumab is experienced, this exposure period can no longer be 
considered ‘continuous’. If such an instance occurs the subject's period of continuous 
mepolizumab treatment will be derived from the first dose of mepolizumab following this 
gap in mep olizumab treatment. 
However, if a subject has experienced a gap of >12 weeks (84 day s) between any  two 
doses of mepolizumab within studies MEA115666 or [ADDRESS_738349] from entry  into 201810.
It is intended that the Follow Up/Exit Visit or Early  Withdrawal (EW) for studies 
MEA115666 and 201312 will serve as the Pre -Screening/Screening Visit (Visit 0/Visit 1) 
for this study . For subjects who are unable to complete the Follow Up/Exit Visit or EW 
from their preceding study  and Visit 1 for this study  on the same day , a Pre -Screening 
2015N232375_03 CONFIDENTI AL
201810
22Visit (Visit 0) is included in order to obtain the signed informed consent, review 
concomitant medications, and perform an exacerbation review. In this case, Visit 1 mus t 
then be completed within 12 weeks (no more than 84 day s) of the last dose in 
MEA115666/201312 to ensure continuous treatment with mepolizumab is maintained per 
inclusion criteria (Section 6.1). It is expected that in most cases, the Pre -Screening Visit 
and Screening Visit will be conducted on the same day . 
A study  schematic is shown in Figure 1. Assessments at each visit are summarised in the 
Time and Events Tables ( Table 5, Table 6, Table 7and Table 8).
Figure [ADDRESS_738350] of care asthma therap y(controller therapy) throughout 
the study . Standard of care will consist of inhal ed corticosteroids ( ICS)and another 
controller, e.g. Long -Acting Beta 2-Agonists (LABA ), with or without maintenance oral 
corticosteroids (OCS) .Standard of care therap ymay have beenadjusted during the 
MEA115666 and 201312 studies and may  be adjusted dur ing the variable open -label run -
in period (Part A) at the discretion of the investigator . During the fixed open -label run -in 
period (Part B) and the double -blind treatment period (Part C), subjects should maintain 
the stable dose and regimen of controller therapy established in Part A or studies 
MEA115666 and 201312 . 
Any change in controller regimen or dose in Part B and Part C (except for OCS use for 
the treatment of exacerbations) should be discussed with the medical monitor. 
Albuterol/salbutamol will be provided to subjects for use on an as needed basis for relief 
of asthma s ymptoms from Visit 1 throughout the study .  
Part A and B: Variable and Fixed Open -Label Run -In Periods
At Visit 1 (Screening), eligible subjects will hav e their exposure period for mepolizumab 
treatment assessed:

2015N232375_03 CONFIDENTI AL
201810
23Subjects with less than 3 years of mepolizumab treatment will enter Part A of 
the study , a variable open -label run -in period on mepolizumab (100 mg SC every  
4 weeks) of [ADDRESS_738351] will enter Part B 
of the study  at Visit B1 and complete a fixed run -in period of 4 weeks (up 
to 8 weeks) during which open -label mepolizumab (100 mg SC every  4 
weeks) is administered, in order to collect baseline information.
Subjects with at least 3years of mepolizumab treatment will directl y enter 
Part B of the stud y. For these subjects, assessments for Visit [ADDRESS_738352] ed on the same day . No assessments should be duplicated.
Part C: Double -Blind Treatment Period
Upon completion of the fixed run -in period Part B, eligible subjects will be randomized 
1:1 to the following double -blind treatment arms at Visit C1:
mepolizumab (100 mg) administered SC every  4 weeks
placebo administered SC every  [ADDRESS_738353] any medical problem s experienced during the study , and any medication taken for 
those medical problems . Any  unscheduled healthcare resource utilization (e.g.; phy sician 
visits, emergency  department visits) due to asthma will also be recorded. 
Subjects will complete a daily electronic diary  (eDiary ) during the fixed run -in Part B,
double -blind treatment period Part C and open -label Part D. Subjects will be asked to 
provide the following information daily :
AM Peak flow before rescue medication usage (L/min)
Rescue medication use
Nocturnal awakening due to asthma sy mptoms requiring r escue medication use
Asthma sy mptoms
Missed day s of work/school due to asthma
Subjects will also be asked to provide the following information via eDiary weekl y:
Asthma Control Questionnaire -5 (ACQ -5)
Part D: Optional Switch to Open -Label Mepolizumab
Subjects who experience a clinically  significant asthma exacerbation during the double -
blind treatment period Part C will require a prompt assessment by  [CONTACT_561910] -blind study  treatment. 
2015N232375_03 CONFIDENTI AL
[ADDRESS_738354] (I P) and complete a 
Discontinuation of I P Visit approximately  [ADDRESS_738355] -randomization. 
No assessments should be duplicated.
Switch to Part D between visits: For example, if a subject completed Visit C7 at Week 24 
(and the subject received a dose of IP at Visit C7) and it is later determined that they  
should switch to Part D, the I P Discontinuation assessments and the first visit in Part D 
will be D8 at Week 28 . 
Switch to Part D during a visit: If a subject is in the process of completing a Part C visit, 
as long as they  have not y et received a dose of IP, they  may  be switched to Part D at that 
same visit (e.g., a subject that is part way  through Visit C7 at Wee k [ADDRESS_738356] 
dose of IP was at Visit C6, Week 20 can be switched to Part D and complete the I P 
Discontinuation assessments and Visit D7 at that same visit, Week 24).
Haematology  samples will be collected for each of the subject’s first 3 visits of P art D, 
and then according to designated Visits in Table 8.
An Exit Visit will be conducted 52 weeks after randomization (whether the subject is in 
Part C or Part D) in order to assess subject’s efficacy  parameters, immunogenicity  status, 
and to conduct additional safet y assessments. 
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . If a subject discontinues double blind study  
treatment during Part C and does not switch to Part D at their next visit (I P 
Discontinuation Visit) after experiencing a clinically  significant asthma exacerbation, the 
subject cannot enter Part D at a later v isit.  
5.2. Stud y Phases, Duration and Treatment A rms
Eligible subjects will participate in the study  ranging from 56 to1 92weeks, depending on 
the duration of Part A (0 to 132weeks) and Part B (4 to 8 weeks). A summary  of study  
phases is described in Table 2.
2015N232375_03 CONFIDENTI AL
201810
25Table 2 Study  Phases, Duration and Study  Treatments
Study 
PhasePhase Title Duration Treatment arms
Part A Variable 
Open -Label 
Run-In0 to 132weeks Open -label mepolizumab (100 mg SC) 
every  4 weeks
Part B Fixed Open -
Label Run -In4 weeks (up to 
8 weeks)Open -label mepolizumab (100 mg SC) 
every  4 weeks
Part C Double Blind 
Treatment 
Period52 weeks Subjects randomized 1:1 to double -blind
study  treatment:
mepolizumab (100 mg SC) every  4 
weeks
placebo administered SC every  [ADDRESS_738357] -
randomization.Open -label mepolizumab (100 mg SC) 
every  4 weeks
5.3. Type and Number of Subjects
Subjects with severe eosinophilic asthma who completed the Follow Up/Exit Visit or EW 
Visit from either open -label study  MEA115666 or 201312 will be eligible to participate 
in this study .
It is estimated that approximately  375 subjects with severe eosinophilic asth ma from 
studies MEA115666 and 201312 are expected to be screened in order to randomize 
approximately  300 subjects 1:1 to double -blind study  treatment (150 per arm). It is 
anticipated that approximately  120 subjects will experience a clinically  significant 
exacerbation and meet the criteria for the Switch to Open -Label Mepolizumab treatment 
within Part D. The sample size calculations assume 20% of subjects will withdraw prior 
to the end of the double -blind treatment phase before experiencing an exacerbation. It is 
anticipated that approximately  [ADDRESS_738358] of care treatment used in a severe asthma population [ ATS,2000;
Chung , 2014].
A primary  endpoint of time to first clinically  significant exacerbation was selected as a 
robust measure to evaluate the return of disease activity  following the discontinuation of 
mepolizumab treatment after long term use. Additional measures of exacerbation severit y 
are also included. As this study  is designed to evaluate withdrawal of treatment after long 
term use, it is anticipated that the rate of discontinuation from Part C may  be high and 
therefore limit the ability to assess exacerbation rate. An optional switch to open -label 
mepolizumab is included in the study  design (Part D) to collect additional safet y data and 
to prevent loss to follow -up. A study  duration of 52 weeks is considered adequate for the
evaluation of exacerbations [ EMA , 2013].
Part A is designed to ensure that all subjects have a duration of mepolizumab treatment of 
at least [ADDRESS_738359] previously  shown to be correlated to increasing exacerbation frequency  
[Haldar , 2014]. Thus, it is important to measure eosinophils as a biomarker of 
mepolizumab activ ity in patients who are withdrawn from mepolizumab treatment after 
long-term treatment. To ensure the integrit y of the blind, eosinophil levels will be blinded 
to both the I nvestigator/site staff and the study  team during Part C and Part D.
The Asthma Cont rol Questionnaire (ACQ -5) will be used to assist the investigator in 
assessing the subject’s asthma status. The ACQ has been validated in several separate 
studies and the minimal clinically  important difference value of ±0.[ADDRESS_738360] rate a significant clinical change in asthma status [ Juniper , 2005 ].
2015N232375_03 CONFIDENTI AL
201810
275.5. Dose Justification
The dose selection is based on previous experience from a Phase 3 program, including 
two Phase 3 placebo -controlled studies (MEA115588 and MEA115575) that 
demonstrated the safet y and efficacy of mepolizumab at a dose of 100 mg SC.
Additionally , this is the same dose that subjects received in precursor studies 
MEA115666 and 201312 . See the IB for additional information.
5.6. Benefit:Risk A ssessment
Summaries of findings from both clinical and non -clinical studies conducted with 
mepolizumab can be found in the IB/IB supplement.   The following section ( Table 3) 
outlines the risk assessment and mitigation strategy for this protocol:
5.6.1. Risk A ssessment
Across the mepolizumab development program, chronic dosing of mepolizu mab up 
to 750 mg intravenous ( IV)every  4 weeks has been associated with an adverse event 
(AE) profile similar to placebo (both dosed in addition to standard of care therapy ),
in the patient populations studied, including mild to moderate asthma and severe
refractory  asthma.  
The majority  of reports of sy stemic non -allergic and allergic (i.e., h ypersensitivity ) 
reactions have been non -serious and resolved without sequelae following minimal 
supportive care. There have been rare reports of serious reactions.
Anti-drug antibodies (ADA) have been observed infrequentl y and have not been 
associated with negative clinical outcomes; there has been no evidence of untoward 
or persistent neutralizing antibodies (N aB) at an y dose.
Infection rates have been similar acr oss treatment groups. The data to date do not 
support an association between treatment with mepolizumab and an increased risk of 
clinically  serious opportunistic or parasitic infections.
Reports of malignancies have been similar between treatment groups in placebo -
controlled trials.  The known biology  of IL -[ADDRESS_738361] malignancy .  
There is a risk of exacerbation in subjects randomized to placebo (in addition to their 
standard of care therap y). An increased exacerbation frequency  was reported in 
subjects withdrawn from mepolizumab after one year of treatment [ Haldar , 2014]. 
However, it is undetermined if certain patients will continue to receive treatment 
benefit after withdrawal of mepolizumab following long -term treatment.
2015N232375_03 CONFIDENTIA L
201810
28Table 3 Risk A ssessment and Mitigation Strategy
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) mepolizumab
Risk of Systemic Allergic and Non -allergic 
Reactions, including AnaphylaxisBiopharmaceutical products administered 
subcutaneously may elicit systemic (e.g. 
hypersensitivity) and local site reactions.
Reactions reported to date across the 
mepolizumab pro gram are summarized in the 
IB; see ‘Special Warnings and Special 
Precautions for Use’ section located in Section 6
titled ‘Summary of Data and Guidance for the 
Investigator’.Daily monitoring of serious adverse events 
(SAEs) by [CONTACT_131989]; regular systematic 
review of adverse event (AE)/SAE data from 
ongoing studies by a [COMPANY_004] safety review team. 
Specific case report form (CRF) pages utilized 
for targeted collection of reac tions data.
Use of Joint NI AID/FAAN 2nd Sy mposium 
on Anaph ylaxis to collect data on reports of 
anaph ylaxis (see Appendix 8).
Safety monitoring of subjects is required during 
SC administration ,in accordance with standard 
of care at the site.
Risk of Immunogenicity Biopharmaceutical products may elicit anti -drug 
antibody (ADA) and neutralizing antibody 
(NaB), which have the potential to modulate 
pharmacokinetic (PK), pharmacodynamic (PD) 
or produce adverse reactions. However, 
humanized and fully human antibodies are less 
immunogenic than mouse or chimeric 
monoclonal antibodies.
Immunogenicity data reported to date across the 
mepolizumab development program are 
summariz ed in the IB; See ‘Clinical Blood samples are colle cted in clinical studies 
for detection of both ADA and N aB.
Monitoring of subjects for immunogenic -related 
events will be done by [CONTACT_561912].
Immunogenicity profile will be updated in the 
Mepolizumab IB as appropriate.
2015N232375_03 CONFIDENTIA L
201810
29Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Immunogenicity’ and a summary of 
immunogenicity findings in the ‘Other 
Potentially Clinically Relevant Information for 
the Investigator’ section titled ‘Summary of 
Data and Guidance for the Investigator’.
Potential risk for adverse cardiovascular (CV) 
effectsMepolizumab binding was restricted to human 
lymphoid tissues in an immunohistochemistry 
tissue binding study suggesting a low likelihood 
of non -pharmacologic effects on CVfunction. 
No AEs concerning cardiac conduction or 
repolarization evident in cynomolgus monkeys 
at doses at least 10 -fold in excess of humans 
dosed at 10 mg/kg or 750 mg.
No clinically relevant trends observed in ECG 
data in humans.
In one study in subjects with severe refractory 
asthma, cardiac events were reported in similar 
frequencies across treatment groups with a small 
numerical increase observed in serious ischemic 
cardiac events in the mepolizumab -treated 
groups. However, an integrated safety analysis 
of all placebo -controlled multiple dose asthma 
trials showed similar frequency of SAEs 
reported overall from the cardiac and vascular 
system organ class (SOC). Additionally, similar 
findings were observed in other SOCs with 
thrombotic events (e.g., stroke in the Nervous Subjects with uncontrolled, severe or clinically 
significant cardiovascular disease are excluded 
from study participation.
Daily monitoring of SAEs by [CONTACT_131989]; 
regular systematic review of AE/SAE data from 
ongoing studies by a [COMPANY_004] safety review t eam.
CV monitoring for study includes:
ECG monitoring during the trial
Use of standardized CRFs to collect 
relevant data on CV events of interest (i.e., 
myocardial infarction, hospi[INVESTIGATOR_561876], 
arterial throm bosis, pulmonary embolism 
and deep vein thrombosis)
2015N232375_03 CONFIDENTIA L
201810
30Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
System SOC) .
Potential risk for increase in infections –a 
theoretical concern with biologics; however, the 
pharmacological properties of mepolizumab 
suggest the risk is low.No evidence of increased incidence of infections 
in any preclinical studies.
Murine data demonstrate that IL -5 antagonism 
is unlikely to influence cellular or humoral 
immunity, particularly in response to parasitic 
infections.  
No mepolizumab -related effects on lymphocyte 
Immunophenotypi[INVESTIGATOR_561877], 
including T -cell activation, distribution of 
CD4/CD8 subtypes or Th1/Th2 cytokine 
patterns, B -cells, NK cells or γδ -T-cells. 
An integrated safety analysis of all placebo -
controlled multiple dose asthma trials showed 
similar reports of infections, including serious 
and opportunistic, across treatment groups 
including placebo. 
Infections reported to date across the 
mepolizumab development program are 
summarized in the IB; see ‘Special Precautions 
and Warnings’ (for exclusion of subjects with 
underlying parasitic infections) and 
‘Undesirable Effects’ (for very common 
infections of nasopharyngitis, upper respi[INVESTIGATOR_19629] ( URTI ), rhinitis and bronchitis 
reported in other patient populations) sectionsDaily monitoring of SAEs by [CONTACT_131989]; 
regular systematic review of AE/SAE data from 
ongoing studies by a [COMPANY_004] safety review team 
Standard safety assessments to be co nducted as 
outlined in protocol
2015N232375_03 CONFIDENTIA L
201810
31Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
titled ‘Summary of Data and Gu idance for the 
Investigator’.
Potential risk for in crease in malignancies -
theoretical concern with biologics; however, 
blockade of IL -[ADDRESS_738362] bo-
controlled multiple dose asthma trials showed 
similar reports of malignancies across treatment 
groups including placebo.
Malignancies reported to date across the 
mepolizumab development program are 
summarized in the IB.Daily monitoring of SAEs by [CONTACT_305807]; 
regular systematic review of AE/SAE data from 
ongoing studies by a [COMPANY_004] safety review team 
Standard safety assessments to be co nducted as 
outlined in protocol
Placebo
Inclusion of placebo arm Mepolizumab has been shown to be an effective 
treatment for the reduction of exacerbations for 
patients with severe eosinophilic asthma. 
There is currentl y no pre -clinical or clinical 
evidence to suggest long -term continuation Both me polizumab and placebo double -blind 
study treatments will be dosed in addition to 
standard of care therapy including corticosteroid 
treatment (ICS or OCS) and a long -acting 
bronchodilator . 
2015N232375_03 CONFIDENTIA L
201810
32Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
of treatment benefit after withdrawal of 
mepolizumab [ Haldar , 2014], however, this 
has not been prospectively  evaluated in 
subjects after long -term treatment with 
mepolizumab.Subjects will be provided with rescue 
albuterol /salbutamol througho ut the study . 
Subject ’s condition will be assessed at clinic 
visits every 4 weeks.
Subjects ’ symptoms and rescue medication 
usage will be tracked daily via eDiary. Subjects
with increasing respi[INVESTIGATOR_561878].
Investigators will also receive alerts, and review 
eDiary data weekly.
Additionally, to minimize the impact of 
significant worsening due to withdrawal of 
therapy over 52 weeks, subjects may optionally 
switch to open -label mepolizumab (Part D) per 
investigator discretion after experiencing one 
clinically significant asthma exa cerbation. 
Potential risk for rebound eosinophilia with 
associated clinical consequencesEarly published data with Schering -Plough 
anti-IL5 mAb suggested potential for 
rebound eosinophilia and disease 
exacerbation when treatment was stopped 
[Kim, 2004; Gevaert , 2006]; however, no 
standard definition of rebound wa s used and 
criteria for reporting were variable. 
There have been no verbatim reports of Daily monitoring of SAEs by [CONTACT_131989]; 
regular systematic review of AE/SAE data from 
ongoing studies by a [COMPANY_004] safety review team 
Standard safety assessments to be co nducted as 
outlined in protocol
2015N232375_03 CONFIDENTIA L
201810
33Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
‘rebound’ from completed clinical trials of 
subjects with asthma, atopic dermatitis and 
eosinophilic esophagitis. Furthermore, the data 
do not support an exaggerated r eturn of 
symptoms after cessation of treatment.
Study Procedures
Potential risk for injury with phlebotomy Risks with phlebotomy include bruising, 
bleeding, infection, nerve damage.Procedures to be performed by [CONTACT_21724] 
(i.e., study nurse) 
2015N232375_03 CONFIDENTIA L
201810
345.6.2. Benefit A ssessment
Data from earlier studies [ Haldar , 2009; Nair, 2009; Pavord , 2012] attest to the clinical 
utility  of mepolizumab in the treatment of severe eosinophilic asthma, as do the data from 
recentl y complete d Phase III studies MEA115575 and MEA115588 [Bel, 2014; Ortega , 
2014] . 
In this stud y, benefit considerations for a subject may  include:
Continuation to receive active drug during study conduct that may have clinical 
benefit, even for subjects randomized to placebo who may  undergo switch to open -
label mepolizumab after experiencing one clinically  significant asthma exacerbation
Contributing to the process of developi[INVESTIGATOR_336243] , and 
providing insight into the need for continuous therapy  in order to receive clinical 
benefit
Medical evaluations/assessments assoc iated with study  procedures
5.6.3. Overall Benefit:Risk Conclusion
Current data from mepolizumab preclinical and clinical development indicate the ability  
of mepolizumab to inhibit IL-5leading to consistent reduction in blood eosinophils , with 
demonstration of clinical benefit in the treatment of conditions associated with 
eosinophili c infl ammation, such as asthma. Data from the Phase III asthma programme 
with mepolizumab demonstra tes, compared to placebo, a reduction in asthma 
exacerbations, improvements in asthma control and quality  of life (as measured b y the 
ACQ and SGRQ, respectively ), improvements in lung function and a reduction in steroid 
use in those subjects on chronic OCS treatment. To date, the safet y profi le of 
mepolizumab compared to placebo has been favorable and AEs reported commonly  are 
non-serious and manageable with minimal supportive care.  Furthermore, evaluation of 
the post -treatment adverse event data from the severe asthma clinical program does not 
support an exaggerated return of s ymptoms after cessation of treatment.
Considering the measures taken to minimiz e risk to a subject participating in this study ,
the potential risks identified are justified b y the an ticipated benefits that may be afforded 
to a subject with severe asthma. Therefore, the Sponsor considers that investigation of the 
effect of cessation versus continuation of long-term mepol izumab treatment in patients 
with severe eosinophilic asthma is ju stified in study 201810 with a positive benefit/risk 
ratio.
6. SELECTION OF STUDY P OPULA TION , IP 
DISCONTINUA TION AND WITHDRAWA L CRITE RIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information o n the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IB/IB supplement(s).
2015N232375_03 CONFIDENTIA L
[ADDRESS_738363] will be eligible for in clusion in this study  only  if ALL of the following criteria 
apply :
1.Informed Consent: Prior to commencing any  study  related activities, subjects 
must be able and willing to provide written informed consent , and an assent for 
subjects under 18 years of age, at Visit 0 (or Visit 1 if these Visits are conducted 
on the same day ).
2.Continuous Mepolizumab Treatment during MEA115666 or 201312: 
Participation through the Follow Up/Exit Visit or Earl y Withdrawal Visit and 
documented evidence of treatment with mepolizumab with no treatment gaps of 
more than 12 weeks (84 day s) between any  two doses within MEA115666 or 
201312.  (A treatment gap of more than 12 weeks [84 day s] cannot occur between 
the end of MEA115666 or 201312 and Visit 1).
3.Current Anti -Asthma Therapy: Asthma is currently  being treated w ith a 
controller medication and the subject has been on a controller medication for the 
past 12 weeks. Subjects will be expected to continue controller therap y for the 
duration of the study .
4.Male or Eligible Female Subjects:
A female is eligible to enter a nd participate in the study  if she is of:
Non-child bearing potential (i.e., phy siologically  incapable of becoming 
pregnant, including an y female who is post -menopausal or surgically  sterile). 
Surgicall y sterile females are defined as those with a document ed hysterectomy  
and/or bilateral oophorectomy  or tubal ligation. Post -menopausal females are 
defined as being amenorrhoeic for greater than 1 year with an appropriate clinical 
profile, e.g., age appropriate, > [ADDRESS_738364] at screening, and agrees to 
acceptable contraceptive methods approved in their local country , when used 
consistently  and correctly  (i.e., in accordance with the approved product label and 
the instructions of the physician )for the duration of the study  and for [ADDRESS_738365] study  drug administration (see Appendix 5).
A urine pregnancy test is required of all females of child -bearing potential at
each scheduled stud y visit prior to the injection of study  treatment, and at the Exit 
Visit, EW or Disc ontinuation of I P Visit .
2015N232375_03 CONFIDENTIA L
201810
365.French subjects: In [LOCATION_009], a subject will be eligible for inclusion in this study 
only if either affiliated to or a beneficiary  of a social securit y category.
6.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study if ANY of the following criteria 
apply :
1.MEA115666 or 201312 IP Discontinuation: Subjects withdrawn from I Por 
withdrawn from stud y participation from either MEA115666 or 201312 for safet y 
reasons
2.Health Status: Clinically significant deterioration i n health status at the completion 
of participation or EW from either the MEA115666 or [ADDRESS_738366] unsuitable for participation in this 
study .
3.Pregnancy: Subjects who are pregnant or breastfe eding. Subjects should not be 
enrolled if they  plan to become pregnant during the time of study  participation.
4.Cardiovascular: Subjects who have severe or clinically  significant cardiovascular 
disease uncontrolled with standard treatment. Including but not limited to:
 known ejection fraction of <30% OR
 severe heart failure meeting [LOCATION_001] Heart Association Class I V 
classification OR
 hospi[INVESTIGATOR_561879] 12 months prior to Visit 1 for severe heart failure meeting 
[LOCATION_001] Heart Association Class III OR
 angina diagnosed less than 3 months prior to Visit 1 or at Visit 1
5.12-Lead ECG: ECG which has a clinicall y significant abnormalit y observed at the 
Screening Visit as determined by  [CONTACT_093]. Subjects with the following 
abnormalities are excluded fro m study  participation: 
 QTcF > 450 msec, or 
 QTcF >480 msec for subjects with Bundle Branch Block.
6.Malignancy: A current malignancy  or previous history  of cancer in remission for 
less than 12 months prior to screening (Subjects that had localized carcinoma of the 
skin which was resected for cure will not be excluded). [ Note for South Korea : 
Korean subjects with a diagnosis of malignancy  within 5 y ears are excluded ].
7.Other Monoclonal Antibodies : Subjects who have received an y monoclonal 
antibody  within 5 hal f-lives of Visit 1. 
8.Adherence: Subjects who have known evidence of lack of adherence within studies 
MEA115666 or 201312 (less than 80%) to controller medi cations, scheduled study  
visits and/or ability  to follow phy sician’s recommendations.
9.Smoking status: Current smokers
2015N232375_03 CONFIDENTIA L
[PHONE_11662].Inability to read: In the opi[INVESTIGATOR_2511] I nvestigator, any  subject who is unable to 
read and/or would not be able to complete a questionnaire.
6.3. Randomization Criteria
6.3.1. Randomization Inclusion Criteria
Subjects are eligible for randomization if ALL of the following are met:
1.Continuous Mepolizumab Treatment: Documented evidence of at least 3years 
(156 weeks) of treatment with mepolizumab with no treatment gaps of more than 
12 weeks (84 day s) between an y two doses while treated with mepolizumab. See 
Section 5.1for the definition of continuou s mepolizumab treatment.
2.eDiary Compliance: Compliance with completion of the eDiary  defined as:
Symptom Scores: Completion of symptom scores on [ADDRESS_738367] 7 day s immediatel y preceding Visit C1.
Rescue Medication Use : Completion of info rmation relating to rescue 
medication use on [ADDRESS_738368] 7 day s immediatel y preceding 
Visit C1.
PEF Measurements: Completion of PEF measurements on [ADDRESS_738369] 7 day s immediately  preceding Visit C1.
Night time awakenin gs requiring rescue medication :Completion of night
time awakenings on [ADDRESS_738370] 7 days immediatel y preceding 
Visit C1.
Subjects who fail this criterion in the run -in Part B may  extend their run -in Part B b y 4 
weeks , and be re -educated on the importance of completion of eDiary  daily  entries .
3.Maintenance Asthma Therapy: No changes in the dose or regimen of baseline I CS 
and/or additional controller medication (except for OCS for the treatment of an 
exacerbation) during the fixed run -in period (Part B).
6.3.2. Randomization Exclusion Criteria
Subjects should not be randomized if ANY of the following are met:
1.Health Status: Clinically significant deterioration in health sta tus during Part A or 
Part B which in the opi[INVESTIGATOR_561880] .
2.12-Lead ECG as assessed a t Visit B1 : ECG which has a clinically  significant 
abnormality  asassessed at Visit B1, as determined by  [CONTACT_093]. Subjects with 
the following abnormalities are excluded from further study  participation: 
QTcF > 450 msec, or 
2015N232375_03 CONFIDENTIA L
201810
38QTcF >480 msec for sub jects with Bundle Branch Block.
3.Liver function asassessed at Visit B1 : 
Alanine transaminase (ALT) >2x upper limit of normal (ULN); and 
Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fraction ated and direct bilirubin <35%)
Current active liver or biliary  disease (with the exception of Gilbert’s s yndro me or 
asymptomatic gallstones or otherwise stable chronic liver disease per investigator 
assessment).
NOTE S: 
Stable chronic liver disease should generally  be defined by  [CONTACT_561913], encephalopath y, coagulopath y, hypoalbuminaemia, oesophageal or 
gastric varices, or persistent jaundice, or cirrhosis.
Chronic stable hepatitis B and C (e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody test result at screening or within [ADDRESS_738371] dose of study  treatment) are acceptable if subject otherwise 
meets entry  criteria
4.Pregnancy: Positive pregnancy  test
5.Immunogenicity: Positive neutralizing antibody  status based on the last result
obtained .
6.Smoking status: Current smokers
7.Current Asthma Exacerbation: Subjects with an asthma exacerbation (or asthma 
worsening) that has not resolved completel y within 7 days of Visit C1. Subjects who 
experience an exacerbation (or asthma worsening) in the fixed run-in Part B which is 
not resolved within 7 days of Visit C1may extend their run -in Part B b y 4 weeks.
6.4. Pre-screen/ Screen/Run -in Failures
Pre-screen/s creen failures /run-in failures are defined as subjects who consent to 
participate in the clinical trial but are never subsequently  randomized. In order to ensure 
transparent reporting of screen failure subjects, meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and respond to queries from 
Regulatory  authorities, a minimal set of screen failure information is required including , 
but not limited to Demograph y, Screen Failur e details, Eligibility  Criteria and Serious 
Adverse Events (see Section [IP_ADDRESS] ).
For the purposes of this study pre-screen/s creen failures /run-in failures will be defined as 
follows:
Subjects will be assigned a study  number at the time of sig ning the informed 
consent (Pre -screen Visit). Subjects who do not progress to the Screening Visit 
will be deemed a pre -screen failure.
2015N232375_03 CONFIDENTIA L
201810
39Those subjects that complete at least one additional Visit 1 (Screening) procedure 
but do not enter the run -in period wil l be designated as screen failures.
Those subjects that enter Part A or Part B , but are not randomi zed, will be 
designated as run -in failures.
Subjects who fail to meet inclusion and exclusion criteria at Visit 1 will be considered 
screen failures and cann ot be re -screened.
6.5. Stud y Withdrawal Prior to Randomization: Withdrawal 
during Part A  or Part B
Subjects have the right to discontinue study  participation before the end of the study . A 
subject may  also be as ked to discontinue study  participation at the inv estigator’s 
discretion or because the subject met the protocol defined stoppi[INVESTIGATOR_561881] .
Subjects in Parts A or B of the study  MUST discontinue study  participation if any  of the 
following stoppi[INVESTIGATOR_23893]: 
1. Liver Chemistry : Meets a ny of the protocol -defined liver chemistry  stoppi[INVESTIGATOR_31732] (see Appendix 2 ).
Liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment 
with the FDA premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati
on/Guidances/UCM174090.pdf
If theliver chemistry  stoppi[INVESTIGATOR_424289] ,treatment restart or re -challenge is not permitted.
2. Pregnancy : Positive pregnancy  test 
3. Laboratory abnormality: Evidence of clinicall y significant abnormality  in the 
haematological orbiochemical screen, which in the opi[INVESTIGATOR_561882] .
4. Hepatitis Status: Positive Hepatitis B Surface Antigen (HBsAg) screen
conducted at Visit 1.
5. ECG :Discontinuatio n is required i f any  of the following ECG criteria are met 
during the stud y:
QTcF>500 msec or uncorrected QT>600 msec
Change from Visit 1 baseline: QTcF> 60msec
2015N232375_03 CONFIDENTIA L
201810
40For patients with underl ying bundle branch block , follow the discontinuation 
criteria listed below:
Visit 1 Baseline QTc with 
Bundle Branch BlockDiscontinuation QTc with 
Bundle Branch Block
< 450 msec > 500 msec
450 –480 msec ≥ 530 msec [Note: QTc(F)>500 
msec for Korean subjects]
Details on performing ECG assessments can be found in Sectio n 8.4.5 .
Subjects who discontinue open -label mepolizumab/withdraw from stud y participation 
during Part A or Part B should return to the clinic for an Earl y Withdrawa l (EW) visit 
(Section 6.6.1 ) and to return an y study materials approximately  [ADDRESS_738372] dose of open -label mepolizumab. No additional follow -up is needed.
Subjects withdrawing from study  participation in Part A or Part B, prior to randomization 
will be classified as run-in failures, as appropriate (Section 6.4). 
6.6. Discontinuation of Investigational Product (IP) during Part C 
or Part D
Subjects in study Part C or D who have permanently discontinued double -blind or 
open -label IP are NOT required to wi thdraw from the study. Subjects have the right 
topermanentl ydiscontinue IPbefore the end of the study . A subject may  also be as ked to 
discontinue I Pat the investigator’s discretion or because the subject met the protocol 
defined IP discont inuation crit eria detailed below .Subjects who discontinue I P, but 
remain in the study  will be treated per local standard of care, according to the judgment 
of the investigator.
Subjects in Parts C or D of the study  MUST discontinue I P permanentl yif either 1, 2 or 3 
of the following stoppi[INVESTIGATOR_23893]: 
1. Liver Chemistry : Meets any  of the protocol -defined liver chemistry  stoppi[INVESTIGATOR_31732] (see Appendix 2 ).
Liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment 
with the FDA premarketing clinical liver s afety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati
on/Guidances/UCM174090.pdf
If the liver chemistry  stoppi[INVESTIGATOR_424289] ,treatment restart or re -challenge is not permit ted.
2. Pregnancy : Positive pregnancy  test 
2015N232375_03 CONFIDENTIA L
201810
413. ECG :Discontinuation is required i f any  of the following ECG criteria are met 
during the stud y:
QTcF>500 msec or uncorrected QT>600 msec
Change from Visit B1 baseline: QTcF> 60msec
For patients with underl ying bundle branch block , follow the discontinuation 
criteria listed below:
Visit B1 Baseline QTc with 
Bundle Branch BlockDiscontinuation QTc with 
Bundle Branch Block
< 450 msec > 500 msec
450 –480 msec ≥ 530 msec [Note: QTc(F)>500 
msec for Korean subjects]
Details on performing ECG assessments can be found in Sectio n 8.4.5.
Subjects in Part C who meet IP discontinuation criteria 1, [ADDRESS_738373] not withdrawn consent may  
continue in the study . Subjects wishing to remain in the study  will complete an IP 
Discontinuation Visit (approximately  [ADDRESS_738374] dose and may  be at the same 
time as a scheduled visit) and continue to attend the clinic visits at the protocol 
designated time intervals and complete eDiary  daily  and weekl y entries for important 
efficacy  and safet y assessments. However, if this is not possib le then the investigator will 
encourage the subject to participate in as much of the study  as they  are willing (or able) 
to. Guidance is provided in the study  reference manual (SRM) and can be used by  [CONTACT_561914] l evel of ongoing stud y participation with 
subjects, after they  have discontinued I P. 
If the subject is unable to visit the clinic to complete an y study assessments which require
physical presence of the subject, visits will occur by  [CONTACT_561915]:
Exacerbations
Adverse Event (AE)/Serious Adverse Events (SAEs)
Concomitant medications
Subjects discontinuing I P, but remaining in the study  should continue to record on their 
paper diary  any medical problem s experienced during the study , and any medication 
taken for those medical problems . 
2015N232375_03 CONFIDENTIA L
[ADDRESS_738375] permanently  discontinues I Pin order to complete 
the IP Discontinuation Visit. E valuations and procedures as outlined in the Time and 
Events Tables ( Table 5, Table 6, Table 7and Table 8) should be completed and r ecorded 
in the eCRF as required.
6.6.2. Reasons for Discontinuation of IP
The primary  reason for permanent discontinuation of I P will be recorded in the eCRF on 
the IP discontinuation form. Specific regard should be given to dis tinguishing permanent 
discontinuation of I P due to an adverse event from other reasons for permanent 
discontinuation of I P.  
6.7. Stud y Withdrawal During Part C or Part D
6.7.1. Study Withdrawal Criteria
For this study  there are no pre -determined protocol specific st udy withdrawal criteria (see
Protocol Defined IP Discontinuation Criteria , Section 6.6).
6.7.2. Study Withdrawal A ssessments
If a subject is withdrawn from the study  for any  reason, including but not limited to the 
Protocol Defined IP Discontinuation Criteria (Section 6.6), the Investiga tor must make 
every  effort to have the subject to return to the clinic for an EWVisit approximately  [ADDRESS_738376] dose to perform EW Visit assessments and to return all study -
related materials. Assessments are described in the Time and Events Tables ( Table 5, 
Table 6, Table 7and Table 8). 
Subjects who have previously  discontinued IP and have alread y completed their I P
Discontinuation Vi sit (approximately  [ADDRESS_738377] dose) but then decide at 
a later date that they no longer wish to participate in the study , will be asked to return to 
the clinic to complete an EW Visit ( approximately  4±1 weeks) to complete any  EW 
assessments, as agreed by  [CONTACT_224092], and to return any  remaining study  
materials. N oadditional safet y follow -up visit is required .
6.7.3. Reasons for Withdrawal
The primary  reason for study  withdrawal will be recorded in the eCRF. Specific regard 
should be given to distinguishing withdrawal due to an adverse event from other reasons 
for withdrawal .  
6.7.4. Lost to Follow Up
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y vis it:
2015N232375_03 CONFIDENTIA L
201810
43The site must attempt to contact [CONTACT_131993] -schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigat or or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_738378]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_561916]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
6.8. Subject and Study  Completion
A subject will be consid ered to have completed study  treatment if he/she rec eives stud y 
treatment at Visit C13 or D13 (Week 48 ). A subject will be considered to have completed 
the study  if they  continue to participate in the study  until the Exit Visit assessments have 
been comple ted (regardless of whether the subject completed the study  treatment 
schedule) .
The end of the stud y is defined as the subject’s last visit.
7. STUDY TREA TMENT
7.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout th e protocol to describe any  combination 
of products received b y the subject as per the protocol design. Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Mepolizumab (SB -240563) is a fully  humanised IgG antibody  (IgG1, kappa) with human 
heav y and light chain frameworks. Mepolizumab will be provided as a l yophilised cake 
in sterile vials for individual use. The vial will be reconstituted with Sterile Water for 
Injection, as described in the SR M.  
The placebo in this study will be 0.9% sodium chloride solution and will be provided b y 
the study  site. 
Trade label albuterol/salbutamol metered dose inhalers (MDI s) will be provided as rescue 
medication throughout the study . Albuterol/ salbutamol wil l be sourced b y [COMPANY_004] for 
centers in the [LOCATION_002] of America. For all other centers it will be sourced locall y 
where possible. Subjects will be dispensed an MDI at the time of Visit [ADDRESS_738379] of care at the site. Such monitoring will include general safet y monitoring 
including monitoring for systemic (i.e., allergic/IgE -mediated and non -allergic) and local 
injection site reac tions. In the event of an acute severe reaction (e.g., anaphy laxis) 
following administration of study  treatment, there are personnel/staff onsite at the 
treatment facility  who are appropriatel y trained in basic life support to manage the 
subject including administration of medications (e.g., epi[INVESTIGATOR_238]), and have access to a 
system that can promptly transport the patient to another facility  for addit ional care if 
appropriate.
7.2. Treatment A ssignment
At the Randomization Visit (Visit C1 ) those subjects who meet the randomi zation 
eligibility  criteria will be randomiz ed in a 1:[ADDRESS_738380] of care asthma treatment:
Mepolizumab 100mg SC into the upper arm or thigh
Placebo 0.9% sodium chloride SC into the upper arm or thigh
Subjects eligible to enter the study  will be assigned to treatment randoml y via an 
interac tive response technology  (IRT) system. 
The randomiz ation schedule will be generated using the [COMPANY_004] validated randomiz ation 
software RandAll NG. The study  will be randomiz ed separatel y for each country.  
Subjects will be assigned to study  treatment in accordance with the randomiz ation 
schedule. Once a randomiz ation number has been assigned to a subject, it cannot be 
reassigned to an y other subject in the study .
7.3. Blinding
Study treatment will be prepared by  a designated unblinded member of the study  site 
staff (i.e. a qualified person who is independent of the protocol -defined study  
assessments) and will be administered b y a designated blinded member of the site staff.  
Once prepared, mepolizumab and placebo will be identical in appearance. The blinding 
of all those involved in the evaluation of the study treatment (e.g. ph ysician/nurse as well 
as the subject) shall be maintained at all times, therefore, procedures must be in -place at 
the study  site to ensure that this blinding is maintained. Additionally , the site staff and 
central stud y team will be blinded to each subject’s eosinophil count (including blood 
count differential) and IL -[ADDRESS_738381], the following will apply :
The investigator or treating ph ysician may  unblind a subject’s treatment assignment 
only in the case of an emergency OR in the event of a serious medical condition 
when knowledge of the study  treatment is essential for the appropriate clinical 
management or welfare of the subject as judged b y the investigator. 
2015N232375_03 CONFIDENTIA L
201810
45Investigators have direct access to the subject’s individual study  treatment. 
It is pre ferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the in vestigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the treatment 
assignment of the unblinded subject, unless that information is important for the 
safet y of subjects currently in the study. 
If the treatment code assigne d to a subject in Part C is unblinded tothe subject,
Investigator and/or the treating ph ysician /blinded member of site staff , please consult 
the Study  Reference Manual and [COMPANY_004] for guidance. Remediation will be assessed on 
a case b y case basis to minimise the impact of an y possible bias.
The date and reason for the unblinding must be fully  documented in the eCRF
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  subject with an SAE. If the SAE requir es that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the subject’s treatment assignment, may  be sent to investigators in 
accordance with local regulations and/or [COMPANY_004] policy .
7.4. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
7.5. Preparation/Handling/Storage/A ccountability
Only  subjects enrolled in the study  may  receive study  treatment and onl y authorized site 
staff may  suppl y or admi nister study  treatment.
A description of the methods and materials required for the preparation of placebo or 
reconstitution of mepolizumab will be detailed in the unblinded staff manual which is 
available in the SRM.
A qualified unblinded site staff membe r assigned to the study  will be required to prepare 
the appropriate study  treatment according to the study  subject’s treatment assignment 
(see Section 7.2for further details on treatment assignment):
Mepolizumab: 1mLof reconstituted mepolizumab (equivalent to 100 mg of 
mepolizumab) will be drawn into a 1 mLpolypropylene sy ringe. 
Placebo: 1mLof 0.9% sodium chloride solution will be drawn into a 1m L
polypropylene s yringe.
A blinded staff member will administer the study treatment into the subject’s upper arm 
or thigh via SC injection. 
2015N232375_03 CONFIDENTIA L
201810
46Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] 
study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
All study  treatments must be stored in a secure environmentally  controlled and 
monitored (manual or automated) area in accordance with the labelled storage 
conditions with access limited to the investigator’s unblinded site staff. 
In accordance with local regulatory  requirements, the investigator’s designated 
unblinded site staff, or head of the medical institution (where applicable) must 
document the amount of investigational product dispensed and the investigator or 
designated blinded site staff will document the amount administered to study subjects. 
The designated unblinded site staff will document the amount returned b y blinded 
staff, and the amount received from and returned to [COMPANY_004], when applicable.  Product
dispe nsing/accountability logs will be maintained by  a designated unblinded member 
of the site staff throughout the study .
Further guidance and information for final disposition of unused study  treatment are 
provided in the SRM. 
7.6. Compliance with Study  Treatmen t Administration
Mepolizumab and placebo will be administered via SC injection to subjects at the study  
site.  Administration will be documented in the source documents and reported in the 
eCRF.
7.7. Treatment of Study  Treatment Overdose
The dose of mepolizumab considered to be an overdose has not been defined. There are 
no known antidotes and [COMPANY_004] does not recommend a specific treatment in the event of a 
suspected overdose. The inve stigator will use clinical judg ment in treating the sy mptoms 
of a suspected overd ose.
7.8. Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study  treatment.
There are no plans to routinely  provide mepolizumab following stud y completion, as 
mepolizumab is expected to be commerciall y available in the countries participating in 
this study .
2015N232375_03 CONFIDENTIA L
[ADDRESS_738382] dose of study  
medication (Visit 1), until the Exit Visit or EW, will be collected and recorded in the 
eCRF (except rescue medication, which is only  recorded in the eDiary ).
Details of non -asthma -related medications take n from the first dose of study medication 
(Visit 1) until the Exit Visit or EW, will be collected and recorded in the eCRF. 
The minimum requirement for recording of concomitant medication is that the drug name 
[CONTACT_561938] .  
7.9.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_561883], e.g. LABA, with or without 
maintenance OCS.
During the fixed open -label period (Part B) and the d ouble -blind treatment period (Part 
C), subjects should maintain the stable dose and regimen of controller therapy established 
in Part A or in studies MEA115666 and 201312 .Any change in controller regimen or 
dose in Part B and Part C (except for OCS use fo r the treatment of exacerbations) should 
be discussed with the medical monitor. 
Additional asthma medi cations such as theoph yllines oranti-leukotrienes will be 
permitted provided that they  have been taken regularly (per label) in the 12 weeks prior 
to randomization (Visit C1 ).  If uncertain whether a medication is permitted please
confirm with the medical monitor.
Albuterol/salbutamol is permitted throughout the study , except in the 6 hour period prior 
to spi[INVESTIGATOR_561884]. Study  provi ded Albuterol/salbutamol should 
NOT be recorded in the eCRF, but will be captured in the eDiary .
LABAs or ICS/LABA fixed dose combinations should be withheld for [ADDRESS_738383]  Pressure (CPAP) for th e treatment of obstructive sleep apnea 
is permitted, if initiated prior to the Screening Visit (Visit 1). This treatmen t must be 
captured in the eCRF.
7.9.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_561885] 201810 study :
2015N232375_03 CONFIDENTIA L
201810
48Table 4 Medications not permitted during the study
Medication s
Investigational drugs (other than mepolizumab)
Other monoclonal antibodies
Experimental anti -inflammatory drugs
Any medication with a significant immunosupressive effect. (some examples listed below )
Methotrexate, troleandomycin, cyclosporin, azathioprine 
Oral gold
Chemotherapy
Regular systemic (oral or parenteral) corticosteroids for the treatment of conditions other 
than asthma
Long acting depot, intramuscular injections of c orticosteroids if used to treat a condition 
other than asthma
Additionally , Bronchial Thermoplasty  and Radiotherapy  are excluded for [ADDRESS_738384] timing of each assessment is listed in the Time and Events Table s,Section 8.1.
2015N232375_03 CONFIDENTIA L
201810
498.1. Time and Events Table s
Table 5 Time and Events Table: Screening/Variable Open -Label Run-In Weeks 0 -52 -Part A
PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Written Informed Consent X
Demography X
Medical History X
Assess cardiac risk factors X
Smoking status X
Inclusion/Exclusion Criteria X
Safety Assessments3
Concomitant Medication X X X X X X X X X X X X X X X X
Physical Examination X X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology X X X X
Chemistry (incl. LFT) X X X X
Pregnancy Test4 U U U U U U U U U U U U U U U
Immun ogenicity X X X
HbsAg and hepatitis C 
antibody X
Efficacy Assessments3
Exacerbation review X X X X X X X X X X X X X X X X
Asthma Control 
Questionnaire -5X X X X X X
2015N232375_03 CONFIDENTIA L
201810
50PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Spi[INVESTIGATOR_038] X X X X
Worksheets /Diary /IP/eCRF
Administer open -label 
mepolizumabX X X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X
Complete eCRF X X X X X X X X X X X X X X X X
1. The Pre -Screen Visit and Screening Visit may occur on the same day.
2. Visits should be conducted every [ADDRESS_738385] has reached 3 years of mepolizumab exposure. 
3. Please see the SRM for details on which screening procedures to perform for subjects entering from 201312 and MEA115666.  ALL procedures should be comp leted prior to 
dosing with open -label mepolizumab.
4. Urine pregnancy tests (U) should be conducted for women of child bearing potential. 
5. EW = Early Withdrawal. Should be conducted 4 ± [ADDRESS_738386]’s last dose
2015N232375_03 CONFIDENTIA L
201810
51Table 6 Time and Events Table: Screening/ Variable Open -Label Run -In Weeks 56 -132-Part A
PART A
ProceduresVariable Open -Label Treatment  Part A1
(window is 1 week)EW
Visit3
Visit A14/A27 A15/A28 A16/A29 A17/A30 A18/A31 A19/A32 A20/A33 A21 A22 A23 A24 A25 A26
Week of Variable Run -In 56/108 60/112 64/116 68/120 72/124 76/128 80/132 84 88 92 96 100 104
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X
Laboratory Assessments
Haematology X X X
Chemistry (incl. LFT) X X X
Pregnancy Test2 U U U U U U U U U U U U U X
Immunogenicity X X
Efficacy Assessments
Exacerbation review X X X X X X X X X X X X X X
Asthma Control Questionnaire -5 X X X X X
Spi[INVESTIGATOR_038] X X X
Worksheets/Diary/IP/eCRF
Administer open -label mepolizumab X X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X
Complete eCRF X X X X X X X X X X X X X X
1. Visits should be conducted every [ADDRESS_738387] has reached 3 years of mepolizumab exposure. 
2. Urine pregnancy tests (U) should be conducted for women of child bearing potential. 
3. EW = Early Withdrawal. Should be conducted 4 ± [ADDRESS_738388]’s last dose
2015N232375_03 CONFIDENTIA L
201810
52Table 7 Time and Events Table: Fixed Run -In & Double -Blind Treatment Period –Parts B and C
PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
Smoking status X
Randomization Criteria X
Safety Assessments2
Concomitant 
MedicationX X X X X X X X X X X X X X X X X X
Physical Examination X X X X X
Vital Signs X X X X X X X X X X X X X X X X X X
12-lead ECG X X X X X
Adverse Events X X X X X X X X X X X X X X X X X X
Laboratory 
Assessments2
Haematology X X X X X X X X X X X X X X X X X
Chemistry (incl. LFT) X X X X X X
Biomarkers X X X X X X X X X
Pregnancy Test [ADDRESS_738389]/Clinician 
Global Impression 
RatingX X X X X X
Subject/Clinician 
Rating of Response to 
TherapyX X X X X
2015N232375_03 CONFIDENTIA L
201810
53PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
SGRQ X X X X X X
Exacerbation review X X X X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] (pre -and 
post-
albuterol/salbutamol)X8 X X X X X X
Healthcare resource 
utilizationX X X X X X X X X X X X X X
Review eDiary4
(symptoms, rescue 
use, nocturnal 
awakenings, PEF, 
ACQ -5, missed days of 
work/school)
Worksheets /Diary /IP/
eCRF2
Administer open -label 
mepolizumab4X X
Administer double 
blind study treatmentX5 X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X X
Collect 
albuterol/salbutamolX X X X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X X
Dispense  eDiary X
Collect eDiary X X X6
2015N232375_03 CONFIDENTIA L
201810
54PARTS 
B&CProceduresFixed
Run-in
Part BEW from 
Part B 7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
Visit
B1 B21Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
[ADDRESS_738390]/review paper 
diaryX X X X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X
Complete eCRF X X X X X X X X X X X X X X X X X X
1. Visit B2 is only intended for subjects who experience an exacerbation in the run-in Part B which is not resolved within 7 days of Visit C1 or subjects who fail eDiary Compliance 
Criteria (Section 6.3). 
2. All assessments to be completed prior to dosing .
3. Urine pregnancy tests (U) should be conducted every [ADDRESS_738391] will be dispensed after Randomization at Visit C1.
6. The eDiary is only collected at an Ear ly Withdrawal visit and not at IPDISC in Part C.
7. IPDISC/EW visit should be conducted 4 ± [ADDRESS_738392]’s last dose
8. Only pre-bronchodilator spi[INVESTIGATOR_561886].
2015N232375_03 CONFIDENTIA L
201810
55Table 8 Time and Events Table: Optional O pen-Label Switch to Mepolizumab –Part D
PART D
ProceduresOPTIONAL Open -Label Switch to mepolizumab Part D1
(window is 1 week)
IPDISC/EW 
Visit8
Visit D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13Exit 
Visit
Week of Study2 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Safety Assessments3
Concomitant Medication X X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology4 X X X X X
Chemistry (incl. LFT) X X X
Pregnancy Test 5 U U U U U U U U U U U U U U U
Immunogenicity X X
Efficacy Assessments3
Exacerbation review X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] X X X X X
Worksheets /Diary /IP/eCRF3
Administer open -label 
mepolizumabX X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Review eDiary6  
(symptoms, rescue use, 
nocturnal awakenings, PEF, 
ACQ -5, missed days of 
work/school)X X X X X X X X X X X X X X X
Collect eDiary X X7
2015N232375_03 CONFIDENTIA L
201810
56PART DProceduresOPTIONAL Open -Label Switch to mepolizumab Part D 1
(window is 1 week)
IPDISC/EW 
Visit [ADDRESS_738393]/review paper diary X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X
Complete eCRF X X X X X X X X X X X X X X X
1.The combined treatment period (Part C) and any switch to open -label mepolizumab (Part D) should not exceed a total duration of [ADDRESS_738394]’s first 3 visits of Part D, and then according to designated Vi sits in Table 8
5.Urine pregnancy tests (U) should be conducted every 4 weeks for women of child bearing potential.
6.The eDiary should be reviewed at each visit. Weekly review is not required in Part D.
7.The eDiary is only collected at an Early Withdraw al or Exit visit.
8.IPDISC/EW visit should be conducted 4 ± [ADDRESS_738395]’s last dose
2015N232375_03 CONFIDENTIA L
2018 10
578.2. Screening and Critical Baseline A ssessments
Informed consent/assent will be obtained at the Pre -screen Visit or Screening Visit (if 
Pre-screen and Screening Visits are performed on the same day ).
8.2.1. Critical procedures performed at Screening (Visit 1)
If the MEA115666 or 201312 Exit Visit/EW and 201810 Screening Visit are conducted 
on different day s (no more than 84 day s apart), the Phy sical Exam, I mmunogenicity  
assessment, and Spi[INVESTIGATOR_561887]. Other assessments 
should be conducted at the Screening Visit.   Please see the Study  Reference Manual 
(SRM) for full details.
Review Inclusion/Exclusion criteria (see Section 6)
Demographic information including gender, ethnic origin, race, year of b irth
Medical history including smoking status, history of sinusitis, nasal 
polyposis, aspi[INVESTIGATOR_270861] , courses of rescue corticosteroids 
Vital signs 
Physical exam
Resting 12 lead ECG   
Therap y history (review concomitant medications from the previous [ADDRESS_738396] dose of study  medication)
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be 
assessed at screening. This assessment must include a review of the subject 
responses to the cardiovascular assessment questions (see Appendix 6 ) 
Exacerbation review 
Smoking status
Asthma Control Questionnaire (ACQ -5)
Spi[INVESTIGATOR_038]  
Laboratory  tests :
Chemistry (including liver function test [LFT])
Haematology  with differential
Immunogenicit y  
Hepatitis B Surface Antigen and hepatitis C antibody
Urine pregnancy  test-for all females of child bearing potential (Follicle 
Stimulating Hormone [FSH]will be assessed to confirm child -bearing 
status, if clinically  indicate d)
AE/SAE assessment 
2015N232375_03 CONFIDENTIA L
2018 10
588.2.2. Critical procedures performed at entry  to Part B (Visit B1 )
Vital signs
Resting 12 -lead ECG
Physical examination
Concomitant medication review
Exacerbation review
Laboratory  tests:
Chemistry  (including LFT)  
Haematology  with differential
Urine pregnancy  test-for all females of child bearing potential
AE/SAE assessment
8.2.3. Critical procedures performed at Randomization (Visit C1 )
History  of previous intubations, asthma exacerbation history  in previous year, 
asthma triggers
Review of randomiz ation criteria (see Section 6.3)
Subject/Clinician global impression of asthma severity  rating
St.George’s Respi[INVESTIGATOR_21606] (SGRQ)
Vital sign s
Physical examination
Spi[INVESTIGATOR_038]  (pre-and post -albuterol/salbutamol)
Review /Collect eDiary  data 
Exacerbation review
Smoking status
Concomitant medication assessment
Laboratory  tests:
Clinical Chemistry (including LFT)
Haematology  with differential
Biomarker sample
Urine pregnancy  test for all females of childbearing potential
AE/SAE assessment
2015N232375_03 CONFIDENTIA L
2018 10
598.3. Efficacy
8.3.1. Efficacy  Endpoints
Efficacy  endpoints are listed in Section 4.
8.3.2. Efficacy  Assessments
The timings of all efficacy  assessments are documented in the Time and Events 
Schedule s(Table 5, Table 6, Table 7and Table 8).
[IP_ADDRESS]. Asthma Exacerbations
Clinically significant exacerbations of asthma are defined b y:
Worsening of asthma which requires use of s ystemic corticosteroids1and/or 
hospi[INVESTIGATOR_31739]/or EDvisits.
1For all subjects, i.v. or oral steroid (e.g., prednisone) for at least [ADDRESS_738397] 3 days is required. 
Clinically  significant exacerbations recorded in the eCRF by [CONTACT_561917] :
 AM peak flow (L /min)
 rescue medication use
 nocturnal awakening due to asthma sy mptoms requiring re scue medication 
use
 symptoms 
In the case that an event described as a clinicall y significant exacerbation is not 
associated with deterioration in at least one of these objective eDiary  parameters, the 
investigator will be asked to provide an explanation to support the decisi on for defining 
the event as an exacerbation.  I n those circumstances where the event cannot be 
supported by  [CONTACT_561918], the case will not be included as a protocol 
defined clinicall y significant exacerbation, but will be included as an inves tigator defined 
exacerbation.  This verification process will be overseen b y [COMPANY_004] clinical staff to ensure 
consistency .Additional details on the process for determination of clinically  significant 
exacerbations can be found in the Reporting and Analysis Pl an (RAP).
Details of each asthma exacerbation, including medications used to treat exacerbations 
should be recorded in the eCRF.
Asthma exacerbations should not be recorded as an Adverse Event unless they meet the 
definition of a Serious Adverse Event.
2015N232375_03 CONFIDENTIA L
2018 10
60Thetime period for collection of exacerbation information in the eCRF will be from the 
time that the I CF is signed until the Exit Visit or EW.
[IP_ADDRESS].1. Guideline for Assessing Multiple Exacerbations
Exacerbations which are separated b y less than 7 days will be treate d as a continuation of 
the same exacerbation .
[IP_ADDRESS]. eDiary  Reporting, Worsening of A sthma and A lerts : Part B, C and D
Subjects should be instructed to bring their eDiary to each Clinic Visit in Part B, Part C 
and Part D.
The subject will be asked to record the f ollowing parameters daily in the eDiary from 
Visit B1 until the completion of Part C or Part D :
Morning peak flow (best of three), before rescue medication usage (L/min). 
Asthma sy mptom score over the previous 24 -hours using a 6 -point scale (Appendix 
7)
Occasions of rescue medication usage over the previous 24 -hours
Frequency  of awakening due to asthma sy mptoms requiring rescue medication use
[IP_ADDRESS].1. eDiary Alerts Indic ating Worsening of Asthma
For safet y the following alerts, indicative of worsening asthma, will be programmed into 
the eDiary  with instructions to contact [CONTACT_561919]. 
NOTE: An alert in itself will not qualify  as a clinically  significant exacerbation:
Decrease in morning PEF 30% on at least two of three consecutive days, compared 
with baseline (last 7 day s of run -inPart B )
A symptom score of 5for at least two of three consecutive days
An increase of 50% in occasions of rescue medication on at least two of three 
consecutive days, compared with the average use for the previous week.
Awakening due to asthma sy mptoms requiring rescue medication use for at least two 
of three consecutive nights.
Sites should revie w subject data weekl y during Part C through a stud y specific web 
portal, and contact [CONTACT_561920] -up as appropriate. Additionally , eDiary  data will 
be reviewed at each clinic visit in Parts C and D by [CONTACT_561921] t o confirm an association between an y exacerbation event and eDiary data.
[IP_ADDRESS].2. eDiary Daily Entry: Missed Days of Work or School
Subjects who work for pay  or go to school on a regular basis will record in the eDiary   
any full and part day s of missed work or scho ol due to asthma. 
2015N232375_03 CONFIDENTIA L
2018 10
[IP_ADDRESS].3. eDiary Weekly Entry: Asthma Control Questionnaire -5 (ACQ -5)
Subjects in Part B, Part C and Part D should complete the ACQ -[ADDRESS_738398]’ asthma control that can be quickly  and easily  completed [ Juniper , 2005].  The 
questions are designed to be self -completed by  [CONTACT_423].  The five questions enquire 
about the frequency  and/or severit y of s ymptoms over the previous week (nocturnal 
awakening on waking in the morning, activity  limitation, and shortness of breath, 
wheeze).  The response options for all these questions consist of a zero ( no 
impairment/limitation) to six (total impairment/ limitation) scale.
[IP_ADDRESS].4. eDiary Compliance
Subjects should be compliant in completing their daily eDiaryentries between each pair 
of on -treatment visits.  Subjects should be ≥80% compliant with completion of t heir 
eDiary . Subjects who are non -compliant (<80%) should be re -educated on the 
requirement fo r dail y diary entry  compliance, and this re -education should be 
documented in the subjects source notes.
[IP_ADDRESS]. Paper Diary
Subjects will be issued a paper worksheet to record adverse events, changes in 
concomitant medications and an y visits to the hospi[INVESTIGATOR_3491]/or emergency department 
during the stud y.Subjects will be asked to bring their worksheet to every  study  visit as it 
will be used to assist subject recall in discu ssions with the investigator, for site staff to 
then enter as appropriate in the eCRF.
[IP_ADDRESS]. Spi[INVESTIGATOR_561888] 1and FVC using the sites own equipment as 
detailed in the Time and Events Tables ( Table 5, Table 6, Table 7and Table 8). 
The spi[INVESTIGATOR_561889] a print out 
of all data generated, which should be stored in the subjec ts source notes. The spi[INVESTIGATOR_561890]’s instructions and a calibration log maintained.
At least 3 acceptable and ideally , 2 repeatable spi[INVESTIGATOR_417445] (from a maximum 
of 8 attempts) should be achieved on each occasion that spi[INVESTIGATOR_561891], in accordance with the American Thoracic Societ y/European Respi[INVESTIGATOR_355632] (ATS/ERS )standards [ Miller , 2005]. At each vi sit, spi[INVESTIGATOR_561892]  (2hours) as the baseline assessment for 
that part of the stud y (i.e., the same time of day as Vis it 1 for Part A, Visit B1 for Part B, 
Visit C1 for Part C) . Subjects should withhold rescue albuterol/salbutamol for 6 hours 
and LABAs or ICS/LABA fixed dose combinations for 12 hours prior to spi[INVESTIGATOR_038] , if 
possible.
2015N232375_03 CONFIDENTIA L
2018 10
62Details on performing the spi[INVESTIGATOR_561893], as well as specific instructions on 
performing the spi[INVESTIGATOR_479917], are documented in the SRM.
[IP_ADDRESS].1. Pre-and Post -Albuterol/Salbutamol Spi[INVESTIGATOR_561894] B and Part C, both pre -and post -
albutero l/salbutamol spi[INVESTIGATOR_496924].  
Bronchodilator responsiveness testing will be completed as follows:
Following pre -albuterol/salbutamol spi[INVESTIGATOR_038] , the subject will self -administer 4 
puffs of albuterol/salbutamol via MDI .  Spi[INVESTIGATOR_561895]  10 to 30 minutes after albuterol/salbutamol administration.
[IP_ADDRESS]. Paper -based A sthma Control Questionnaire -5 (Part A  only )
Subjects in Part A of the study  will complete the ACQ -5 at specified clinic visits ( Table 5
and Table 6) on paper, and their responses will be entered by  [CONTACT_561922]. 
Note: I n parts B, C and D the ACQ -5 will be completed by  [CONTACT_561923]  
(Section [IP_ADDRESS].3 ).
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_21606] (SGRQ)
The St. George’s Respi[INVESTIGATOR_417442] a well established instrument, comprising 
[ADDRESS_738399] , taking on average 20 minutes [Jones , 1992] with a recall 
over the past 4 weeks. It has been used successfully in studies of chronic obstructive 
pulmonary  disease (COPD )and asthma subjects and has been translated and validated for 
use in most major languages.  Re search has demonstrated that it is sensitive to change ,
and interpretation of the results has been enhanced by  [CONTACT_561924] a clinically  meaningful improvement in quality  of life [ Jones , 2002].  
Additional instructions for the completion of SGRQ are provided in the SRM.
[IP_ADDRESS]. Subject/Clinician Rating of Global Impression of Disease Severity and 
Response to Therapy
The Global Impressions of Disease Severit y and Response to Therap y should be the first 
procedure completed b y the subject and clinician (Primary  or Sub I nvestigators) at the 
specified stud y visit. To avoid biasing responses, the subjects should not be told the 
results of diagnostic tests prior to completing the questionnaire sand these questionnaires 
should be completed before an y procedures are performed on the subject to avoid 
influencing the subject’s and Investigator’s response.
Additional instructions will be found in the SRM.
2015N232375_03 CONFIDENTIA L
2018 10
63Global Impression of Disease Severity: The investigator (or designee) and subject will 
complete a Global Impression o f Disease Severity question at R andomisation and visits 
described in Table 7. This single global question will ask subject sand clinicians to rate 
the subject’s asthma severity  on a four -point scale (mild, moderate, severe, very  severe).
Response to Therapy: The investigator (or designee) and subject will also be asked to 
rate the subject’s response to therap y at specified visits ( Table 7). This is an overall 
evaluation o f response to treatment, as compared to Visit C1 . This will be conducted 
separately  by [CONTACT_093] (or designee) and the subject using a seven -point rating 
scale as follows: 
1 = significantly  improved 
2 = moderatel y improved 
3 = mildly  improved 
4= no change 
5 = mildly  worse
6 = moderatel y worse
7 = significantly  worse 
[IP_ADDRESS]. Healthcare Resource Utilization
All unscheduled asthma -related visits to a phy sician’s office, visits to urgent care, visits 
to the emergency  department, and hospi[INVESTIGATOR_561896]’s asthma 
will be recorded in the eCRF.
At Visits C2 through the Part C Exit Visit or EW, theresource utilization work sheet used 
by [CONTACT_561925] (or designated coordinator).  The investigator (or designated 
coordinator) should ask the subject if any of the health care contact s that are recorded on 
the worksheet were due to asthma .  The investigator can refer to his/her records to verify  
or supplement information given b y the subject, if necessary . 
If any unscheduled healthcare contact [CONTACT_561926] t o an asthma exacerbation, then the Asthma
Exacerbation section of the eCRF must be completed.
Details regarding completion of the Healthcare Utilization worksheet are located in the 
SRM.
8.4. Safet y
Planned time points for all safety  assessments are listed in t he Time and Events Table s
(Section 8.1).  
See Section 4for details of the safet y endpoints to be assessed in the stud y.
8.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 4.
2015N232375_03 CONFIDENTIA L
2018 10
64Adverse Event sinclude sy stemic (i.e., allergic/IgE -mediated and non -allergic) and 
injection site reac tions reported throughout all study  treatment periods . If the investigator 
considers that there is a reasonable possibility  that the Sy stemic reaction (e.g., 
Hypersensitivity ) or Local injection site reaction event is related to investigational 
product, then additional information about the t ype of reaction and whether it meets 
anaph ylaxis criteria will be collected in the eCRF.
NOTE: Hy persensi tivity  reactions will be monitored using the diagnostic criteria for 
anaph ylaxis as outlined by  [CONTACT_941] 2006 Joint NI AID/FAAN Second Sy mposium on 
Anaph ylaxis [ Sampson , 2006] (Appendix 8).  Information will be also collected from 
subjects to help with the assessment of potential localised injection site reactions.
The investigator a nd their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
AEs will be collected from the Screening visit (Visit 1), until th e Exit Visit or EW
(see Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events Table s
(Section 8.1).
Medical occurrences that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
Any SAEs assessed as related to study  participation (e.g., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
concomitant medication will be recorded from the time a subject consents to 
participate in the study  up to and including an yExit Visit or EW.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
Appendix 4.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been dis charged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus proce dures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 4
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AE s and/or SAEs. Open -ended 
and non -leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/con tact?” 
2015N232375_03 CONFIDENTIA L
2018 10
65“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent vis its/contacts.  All SAEs, and non -serious AEs of special interest 
(as related to the identified and potential risks described in Table 3) will be followed until 
resolut ion, until the condition stabilizes, until the event is otherwise explained, or until 
the subject is lost to follow -up (as defined in Section 6.7.4 ). Further infor mation on 
follow -up procedures is given in Appendix 4.
[IP_ADDRESS]. Cardiovascular and Death Events
[IP_ADDRESS].1. Cardiovascular Events
Cardiovascular -related AEs and SAEs that will require the investig ator to complete event 
specific pages in the eCRF are listed in Section 13.4.3 .
Cardiovascular events information should be recorded on the corresponding eCRF pages
within one week of when the AE/SAE(s) are first reported.  Please refer to Appendix 4
for timelines for reporting AE/SAEs.
[IP_ADDRESS].2. Death Events
In addition, all deat hs will require completion of a specific death data collection page in 
the eCRF.  The death data collection page in the eCRF includes questions regarding 
cardiovascular (including sudden cardiac death) and non -cardiovascular death.
Death information should be recorded on the death eCRF page within one week of when 
the death is first reported.
Please refer to Appendix 4for timelines for reporting SAEs.
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_427220] (even 
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  autho rity and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Indepen dent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
2015N232375_03 CONFIDENTIA L
2018 10
66An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirement s.
8.4.2. Pregnancy
Details of all pregnancies in female subjects will be collected after the start of 
dosing (Visit 1) until the Exit Visit or EW
Based on the absence of an identified reproductive hazard from preclinical studies, 
absence of a genotoxic potential , and very  low levels of mepolizumab that might be 
present in semen, there is no recognized risk for mepolizumab to affect human sperm 
or the fetus if transferred to a female partner via semen. Therefore, the use of 
condoms or other methods of contracepti on in the male study  subject is not required.
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 
weeks of learning of the pregnancy  and should follow the procedures outlined in
Appendix 5.
8.4.3. Physical Exams
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointestinal and Neurological s ystems. Height and 
weight will also be measured and recorde din the eCRF . 
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
8.4.4. Vital Signs
As detailed in the Time and Events Schedule s(Table 5, Table 6, Table 7and Table 
8) vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_738400] and will 
include systolic and diastolic blood pressure and heart rate.
Vital signs assessments will be taken befor emeasurement of an y clinic lung 
function tests or ECGs at the specified time point.
8.4.5. Electrocardiogram (ECG)
Twelve -lead ECGs will be obtained at each time point specified in the Time and 
Events Schedule s(Table 5, Table 6, Table 7and Table 8).
ECG machines that automatically  calculate the heart rate and measure PR, QRS, QT, 
and QTc intervals will be provided b y [COMPANY_004] via a designated central laboratory.
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula 
may not be changed or substituted once the subject has been enrolled.
For example, as a subject is eligible f or the stud y based on QTcF , then QTcF 
must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , 
the same formula must continue to be used for that subject for all QTc da ta 
2015N232375_03 CONFIDENTIA L
2018 10
67being collected for data analysis .  Safety  ECGs and other non -protocol 
specified ECGs are an exception.  
The QTc should be based on the average QTc value of triplicate ECGs. For 
example, if an ECG demonstrates a prolonged QT interval, obtain two more 
ECGs over a brief period, and then use the averaged QTc values of the three 
ECGs to determine whether the patient should be discontinued from the 
study .
ECG measurements will be made after the subject has rested in the supi[INVESTIGATOR_131962] 5 minutes.  The EC G should be obtained after the vital signs assessments but 
before lung function testing followed b y other study procedures.  Collection shortly 
after a meal or during sleep should be avoided since QT prolongation can occur at 
these times.
Paper ECG traces will be recorded at a standard paper speed of 25mm/sec and gain 
of 10mm/mV, with a lead II rh ythm strip. There will be electronic capture and 
storage of the data b y a validated method.
Paper ECG traces are required to be maintained at the site with other source 
documents.
Refer to Section 6.5and Section 6.6for QTc withdrawal and discontinuation of I P 
criteria.
8.4.6. Clinical Safety  Laboratory  Assessments
All protocol required laboratory  assessments (haematology andclinical chemistry ) must 
be conducted in accordance with the Laboratory  Manual, and Protocol Time and Events 
Schedule ( Table 5, Table 6, Table 7and Table 8).Laboratory requisition forms must be 
completed and samples must be clearl y labelled with the sub ject number, protocol 
number, site/centre number, and visit date. Details for the preparation and shipment of 
samples will be provided by  [CONTACT_561927]. 
Standard r eference ranges for all safet y parameters will be provided to the site by  [CONTACT_561928].
All blood samples should be taken pre -dose, and will be sent to a central laboratory  for 
analysis or for shipment to a [COMPANY_004] laboratory (details provided in the L aboratory  
Manual). 
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) th e results must be recorded in the eCRF. Please note that any  non-
protocol specified local laboratory  result has the potential to break the blind due to the 
eosinophils result being available.  Please see the Study  Reference Manual for guidance.
Refer to the Laboratory  Manual for appropriate processing and handling of samples to 
avoid duplicate and/or additional blood draws. 
2015N232375_03 CONFIDENTIA L
2018 10
68Haematology , clinical chemistry and additional parameters to be tested are listed in Table 
9.
Table 9 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline p hosphata se Albumin
Other 
Screening 
TestsHepatitis B (HBsAg)
Hepatitis C (Hep C antibody )2
FSH and estradiol ( if clinically  indicated, in women of non -child 
bearing potential onl y)
Alcohol and drug screen ( if clinically  indicated, to include at 
minimum: amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], 
cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (for women of child bearing potential)3
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after live r stoppi[INVESTIGATOR_97177] [ADDRESS_738401] -
randomization.
[IP_ADDRESS]. Immunogenicity
Blood samples will be collected for the determination of anti -mepolizumab antibodies, 
prior to dosing, as detailed in the Time and Events Schedule s (Table 5, Table 7and Table 
8). 
Details for sample collection and processing may  be found in the SRM.
8.5. Biomarker(s)/Pharmacody namic Markers
The following tests will be performed on the blood sample: 
Blood eosinophil counts will be recorded as part of the standard haematological
assessments performed at the visits specified in the Time and Events Schedule s(Table 5, 
Table 6, Table 7and Table 8). The site staff and central study  team will be blinded to 
each subject’s eosinophil count (including blood count differential) from any visits post -
randomization.
Blood (serum) samples will be collected during this study  and may  be used for the 
purposes of measuring biomarkers to identify  factors that may  influence the development 
of asthma and/or medically  related conditions, as well as the biologica l and clinical 
responses to mepolizumab. Blood samples for biomarker testing will be stored for up to 
[ADDRESS_738402] previousl y been obtained from precursor studies:
MEA112997, MEA115588, and MEA115575 . These samples may be used as part of a 
genetic analy sis using data collected in this study , if relevant.  No additional genetic 
samples are required.
9. DATA MANAGEMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to[COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.   
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
2015N232375_03 CONFIDENTIA L
2018 10
70Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug .  
CRFs (including quer ies and audit trails) will be retained by  [CONTACT_23983], and copi[INVESTIGATOR_131964] y.  Subject initials , 
date of birth or other personally  identifiable information will not be collected or 
transmitted to [COMPANY_004] accor ding to [COMPANY_004] policy .
10. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
10.1. Hypotheses
The study  is designed to test the superiority  of continued mepolizumab 100 mg SC 
treatment vs. mepolizumab discontinuation ( placebo ).Significance tests will be 
performed at the tw o-sided 5% alpha level (one -sided 2.5%).
10.2. Sample Size Considerations
Sample size is based on the primary  efficacy  endpoint of time to first clinically  
significant exacerbation .
10.2.1. Sample Size A ssumptions
With a sample size of 300 randomised subjects (150 per a rm), it is estimated that 
statistical significance will be declared if the proportion of subjects with a clinically  
significant exacerbation following withdrawal of mepolizumab is 52.5% compared to 
40% for those continuing to receive mepolizumab (hazard ra tio = 0.686).
If the true hazard ratio is 0.55 (corresponding to a proportion with an exacerbation 
following discontinuation of mepolizumab of 60.5%), then the study  has a probability  of 
90% of observing a hazard ratio of < 0.686 and therefore the study  has 90% power for 
declaring statistical significance on this endpoint.
The estimated event rate for subjects randomized to mepolizumab is based on interim 
data from stud y MEA115666 which suggests 40% of subjects will experience an 
exacerbation within one y ear of randomization.   In study  MEA115588, the observed 
hazard ratio for the combined treatment arms of mepolizumab 100mg SC and 75mg SC 
vs placebo was 0.5.  A lower event rate among those discontinuing mepolizumab is 
expected in this study  than was observ ed for placebo in MEA115588 because of the 
continuing effects of previ ous treatment with mepolizumab. The sample size calculations 
assume 20% of subjects will withdraw prior to the end of the double -blind treatment 
phase before experiencing an exacerbation.
10.2.2. Sample Size Sensitivity
If the true hazard ratio or proportion of events seen within the mepolizumab 
discontinuation (placebo) treatment group observed within this study  differs from the 
2015N232375_03 CONFIDENTIA L
[ADDRESS_738403] 
ratios and proportion of events observed within the mepolizumab discontinuation 
(placebo) group , assuming a sampl e size of [ADDRESS_738404] ratios and proportions of events 
observed within the mepolizumab discontinuation (placebo) 
treatment group
Proportion 
of events 
within the 
placebo 
groupHazard ratio
0.40 0.45 0.50 0.55 0.60 0.65 0.70
50% 98.6% 96.0% 90.9% 82.6% 71.3% 58.0% 44.3%
55% 99.2% 97.5% 93.6% 86.4% 75.8% 62.5% 48.1%
60% 99.6% 98.5% 95.5% 89.5% 79.8% 66.7% 51.8%
65% 99.8% 99.1% 97.0% 92.1% 83.3% 70.6% 55.5%
10.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study .
10.3. Data Analysis Considerations
10.3.1. Analysis Populations
All Subjects Enrolled (A SE) Population
The ASE population will comprise all subjects enrolled and for whom a record exists on 
the study  database. This population will be used for summarising reasons for screen and 
run-in failures and to report data collected within the variable open -label run -in (Part A) 
and fixed run -in (Part B) .
Intent -to-Treat (ITT) Population
This population will consist of all randomi zed subjects who receive at least one dose of 
double -blind study medication, and will be the primary  population for all analy ses of 
efficacy  and safet y data. In cases where there is a discrepancy  between the trea tment to 
which a subject was randomi zed and the treatment they  actuall y received a profile of the 
subjects’ data will be produced.
2015N232375_03 CONFIDENTIA L
2018 10
72Per Protocol (PP) Population
The PP population will consist of all subjects in the ITT population who have not been 
identified as full protocol deviators with respect to criteria that are considered to impact 
the primary  efficacy  analy sis. The decision to exclude a subject from the PP Population 
or exclude part of their data from the PP Population anal yses will be made prior to 
breaking the blind. The PP population will be used for a supplementary  analy sis of the 
primary  endpoint.
10.3.2. Interim A nalysis
No interim anal ysis of data is planned for this study .
10.4. Key Elements of A nalysis Plan
Full details of all anal ysis methods to be used will be provided in the RAP which will be 
finalised prior to unblinding .
The study  will be unblinded once the final subject has completed the Exit or EW V isit, all 
queries for data collected up to this time are resolved and the clinical study  datab ase is
frozen.
10.4.1. Primary  Analyses
Time to first clinically  significant exacerbation will be compared between treatment 
groups using a Cox’s proportional hazards model allowing for covariates of region, 
exacerbations in the year prior to randomi zation and use of baseline maintenance oral 
corticosteroids (OCS vs no OCS) .For geographical region, a groupi[INVESTIGATOR_007] s ystem for 
countries will be defined in the RAP.
Only  Part C exacerbation data will be included in the primary  anal ysis from the start of 
double -blind treat ment until no greater than [ADDRESS_738405]-dose of double -blind 
treatment. The anal ysis will be performed on the Intent -to-Treat (ITT) population. A 
supporting analy sis of the PP population will also be performed.
10.4.2. Secondary  Analyses
For subjects that com plete Part C of the study , data will be included in the anal ysis of the 
secondary  and other endpoints from the start of double -blind treatment until the Exit visit
date.  For those subjects that switch to open -label Part D, discontinue I P early  or earl y 
withdraw from the stud y altogether, data will be included from the start of double -blind 
treatment until no greater than approximately  [ADDRESS_738406]-dose of double -blind 
treatment.  Data collected following the switch to open -label treatment within Part D or 
IP discontinuation will also be omitted from the analy sis of the these endpoints.
Ratio to baseline in blood eosinophil count will be anal ysed using mixed models repeated 
measures adjusting for the aforementioned covariates within the primary  analy sis and 
visit, plus interaction terms for visit by  [CONTACT_561929].
2015N232375_03 CONFIDENTIA L
2018 10
73Time to a decrease in asthma control, defined as an increase from baseline in Asthma 
Control Questionnaire -5 (ACQ -5) score of ≥ 0.5 units, will be compared using a Cox’s 
proportional hazards model ,as described for the primary  endpoint.
Time to first exacerbation requiring hospi[INVESTIGATOR_561897] a 
Cox’s proportional hazards model ,asdescribed for the primary  endpoint.
10.4.3. Other A nalyses
[IP_ADDRESS]. Efficacy Analyses
See Section 4for a list of all other efficacy  endpoints. Full details of any  analy ses to be 
performed on these endpoints will be provided in the RAP .
[IP_ADDRESS]. Safety  Analyses
Summaries of data will report data according to the nominal visit for which it was 
recorded. Further details will be provided in the RAP.
[IP_ADDRESS].1. Extent of Exposure
The number of subjects administered investigational product, the number of treatm ents 
administered and the number of day s over which treatment was administered will be 
summarised.
[IP_ADDRESS].2. Adverse Events
Adverse Events (AEs) will be coded using the standard Medical Dictionary  for 
Regulatory  Activities (MedDRA) and will be grouped by  [CONTACT_386001] n class. AEs will be 
summarised by  [CONTACT_561930], by  [CONTACT_561931]. Separate summaries will be presented for all 
AEs, drug -related AEs, serious AEs (SAEs), AE ’s leading to permanent discontinuation 
of study  treatment or withdrawal from study  and for any  AEs of special interest.
[IP_ADDRESS].3. Clinical Laboratory Evaluations
Haematology  (including blood eosinophils) and clinical chemistry  data will be 
summarized at each scheduled assessment. The proportion of values outside of the 
normal reference range and those meeting the criteria for potential clinical significance 
will also be summarised. Further details will be provided in the RAP.
[IP_ADDRESS].4. Other Safety Measures
Actual values and change from baseline for other scheduled safet y assessments will be 
summarized at each visit per the Time and Events schedule ( Table 5, Table 6, Table 7, 
Table 8). Further det ails will be provided in the RAP.
[IP_ADDRESS].5. Immunogenicity
Immunogenicit y data will be summarised using appropriate descriptive statistics.
2015N232375_03 CONFIDENTIA L
[ADDRESS_738407] previousl y been obtained from precursor studies:
MEA112997, MEA115588, and MEA115575 . These samples may be used as part of a 
genetic analy sis using data collected in this study , if relevant.  No additional genetic 
samples are required.
11. STUDY GOVERNANCE CON SIDERATIONS
11.1. Posting of Information on Publicly  Available Clinical Trial
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
11.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with International 
Conference on Harmonization (ICH)Good Clinical Practice (GCP) and applicable 
country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of t he study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writ ing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority , approve the clinical 
protocol and all optional assessments, including genetic research. 
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
2015N232375_03 CONFIDENTIA L
2018 10
75Approval of the optional assess ments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
11.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_561932] w ith the 
site staff the protocol, study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF 
will serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accord ance with the currently approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
11.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completio n of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
11.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or pre maturel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
2015N232375_03 CONFIDENTIA L
2018 10
76If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applic able, of the 
impending action.
If the stud y is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will a lso promptly  
inform the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where ap plicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
11.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain al l site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspectio n) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard copy  (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet a ccessibility  and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dic tated by  
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off-site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
2015N232375_03 CONFIDENTIA L
[ADDRESS_738408] of Mepolizumab in Eosinophilic Asthma. N Engl J Med 
2014 September 8;371(13):1189 -97.
Chung KF, Wenzel SE, Brozek JC et al. International ERS/ATS guidelin es on definition, 
evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343 -373.
Cohn L , Elias JA, Chupp GL .  Asthma: mechanisms of disease persistence and 
progression.  Ann Rev Immunol 2004;22:789 -815.
Collins PD, Marleau S, et al. Cooperation between interleukin -5 and the chemokine 
eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995; 182(4):1169 -74.
European Medicines Agency  (EMA) .Note for guidance on clini cal investigation of 
medicinal products for treatment of asthma .2013 Draft. CHMP/EWP/2922/01 Rev.1 .
Gevaert P, Lang -Loidolt D, Lackner A, et al. Nasal IL -5 levels determine the response to 
anti-IL-5 treatment in patients with nasal poly ps.  J Allergy  Clin Immunol
2006;118:1133 -41.
Global Strategy  for Asthma Management and P revention, Global I nitiative for Asthma 
(GINA ) 2015 . Available from: http://www.ginasthma.org/ .
Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory  
eosinophilic asthma. N Engl J Med. 2009;360:973 -984.
Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W et al.  
Outcomes after cessarion of mepolizumab therap y in severe eosinophilic asthma: A 12 -
month follow -up anal ysis.  J Allergy Clin Immunol 2014;133:921 -23.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, editors. 
Contraceptive Technology . 20th edition.  Atlanta, Georgia: Ardent Media, Inc., 2011:50. 
Table 3 -2.
ICH guideline M3(R2) on non -clinical safety  studies for the conduct of human clinical 
trials and marketing authorisation for pharmaceuticals, 2009; EMA/CPMP/ICH/286/[ADDRESS_738409] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Jones PW, Interpreting thresholds for a clinically  significant change in health status in 
asthma and COPD. Eur Resp ir J.2002;19 :398-404.
Jones PW, Quirk FH, Bavey stock CM, Littlejohns P. A self -complete measure for 
chronic airflow limitation -the St George's Respi[INVESTIGATOR_21606]. Am Rev Respir 
Dis1992;145:[ADDRESS_738410] åhl E. Mea surement properties and interpretation of 
three -shortened versions of the asthma control questionnaire. Resp Med 2005;99:553 -
558.
Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of 
hypereosinophilic sy ndrome and eosinophilic gastro enteritis with monoclonal anti –IL-5 
antibody  SCH55700. J Allergy Clin Immunol 2004;114:1449 -55.
Le Gal F, Gordien E,Affolabi D, Hanslik T,Alloui C, Dény P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicate s 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients .  J Clin Microbiol. 2005 ;43(5): 2363 –2369.
Lopez AF, Sanderson CJ, Gamble JR, et al.  Recombinant human interleukin -5 is a 
selective activator of human eosinophil function.  J Exp Med 1988;167:219 -24.
Miller MR et al. (2005) Standardization of L ung Function Testing. Eur Resp J; 26:[ADDRESS_738411] M et al. Mepolizumab for prednisone -dependent 
asthma with sputum eosinophilia. N Engl J Med. 2009 ;360:[ADDRESS_738412] ID, Brusselle GG, FitzGerald JM, Chetta A et al. 
Mepolizumab Treatment in Patients with Severe Eo sinophilic Asthma. N Engl J Med 
2014 September 8;371(13):[ADDRESS_738413] ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma 
(DREAM): a multicentre, double -blind, placebo -controlled trial. Lancet 2012;380:651 –
59.
Proceedings of the AT Sworkshop on refractory  asthma: current understanding, 
recommendations, and unanswered questions. Am J Respir Crit Care Med
2000;162:2341 -2351.
Sampson HA, Munoz -Furlong A, Campbell RL , et. al . Second sy mposium on the 
definition and management of anaph ylaxis: summary  report --Second National I nstitute of 
Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis Network symposium. J 
Allergy Clin Immunol 2006;117:391 -397.
Sanderson, CJ. I nterleukin -5, eosinophils, and disease.  Blood 1992; 79(12):3101 -9.
Sumitas K, Radinger M and Bossios A.  Current update on eosinophilic lung diseases and 
anti-IL-5 treatment.  Recent Patents Anti -inf Drug Disc 2011;6:189 -205.
The ENFUMOSA cross -sectional European multicentre stud y of the clinical phenotype 
of chronic seve re asthma. European Network for Understanding Mechanisms of Severe 
Asthma.  Eur Respir J 2003;22:[ADDRESS_738414]  inflammation in the management of asthma. J Asthma Allergy . 2011;4: 77 –86.
Walsh ER, Stokes K, August A . The Role of Eosinophils in Allergic Airway  
Inflammation . Discovery Medicine , 2010, 47:357 -362.
Wenzel SE. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149 -160.
2015N232375_03 CONFIDENTIA L
[PHONE_11663]. APPENDICES
13.1. Appendix 1 : Abbreviations and Trademarks
Abbrev iations
ACQ Asthma Control Questionnaire
ADA Anti-Drug Antibody
AE Adverse Event
ALT Alanine Transaminase
ASE All Subjects Enrolled
AST Aspartate Transaminase
ATS American Thoracic Society
BP Blood Pressure
COPD Chronic Obstructive Pulmonary  Disease
CPAP Continuous Positive Airway  Pressure
CPK Serum Creatine P hosphokinase
CRP C-Reactive Protein
CS Corticosteroid
CV Cardiovascular
DNA Deox yribonucleic acid
ECG Electrocardiogram
eCRF Electronic Case Report Form
ED Emergency  Department
eDiary Electronic Diary
ERS European Respi[INVESTIGATOR_561898] [ADDRESS_738415] C High Performance Liquid Chromatograph y
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization
ICS Inhaled Corticosteroids
IEC Independent Ethics Committee
Ig Immunoglobulin
2015N232375_03 CONFIDENTIA L
[ADDRESS_738416]
ITT Intent to Treat
IV Intravenous
IRT Interactive Response Technology
kg Kilogram
L/min Liters per minute
LABA Long -Acting Beta -2-Agonists
LFT Liver Function Test
mAb Monoclonal Antibody
MedDRA Medicinal dictionary  for regulatory  activities
mcg ( g) Microgram
mcL (L) Microliter
MDI Metered Dose Inhaler
mg Milligram
mL Milliliter
N/A Not Applicable
NaB Neutralizing Antibodies
NIAID National Institute of Allergy  and Infectious Diseases
OCS Oral Corticosteroids
PD Pharmacod ynamic
PEF Peak Expi[INVESTIGATOR_561899] b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Fridericia’s formula
RAP Reporting and Anal ysis Plan
RNA Ribonucleic acid
SAE Serious Adverse Event
SC Subcutaneous
SGRQ St. George’s Respi[INVESTIGATOR_561900] D
SRM Study  Reference Manual
ULN Upper Limit of Normal
URTI Upper Respi[INVESTIGATOR_168002]
2015N232375_03 CONFIDENTIA L
201810
83Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_561933]
2015N232375_03 CONFIDENTIA L
[PHONE_11664].2. Appendix 2: Liver Chemistry  Stoppi[INVESTIGATOR_424311] A lgorithm
Phase III -IVLiver Chemistry Stoppi[INVESTIGATOR_301074] A lgorithm
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 3.Cont inue Study Treatment 
Discont inue Study Treatm ent Plus 
Biliru bin≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measur ed*
Possi ble  
Hy’sLawALT≥3xULNALT
≥8xULNPlus
Sympt oms of 
liver injury
or 
hyper sensitivityNo
Yes
Yes YesNo No NoSee algorithm 
for continued 
therapy with 
increase d liver 
chemi stry 
moni toring
Yes
*INR value not applicable to subjects on anticoagu lants ALT 
≥3xULN 
but 
<8xULNYes
Must  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirub in≥2xULN (>35% direct)  or 
INR>1.5, if measur ed*
2015N232375_03 CONFIDENTIA L
201810
85Phase III -IV Liver Chemistr y Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 3.Continue Study Treatm ent   and   Monitor Liver Chemistry
Discontinue Study T reatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust refer to Liver Safety Requi red Actions  and Follow up Asses sments section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor   
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other 
stop pi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other  
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measur ed*
2015N232375_03 CONFIDENTIA L
[PHONE_11665].3. Appendix 3: Liver Safety  Required A ctions and Follow up 
Assessments
Phase II I-IVliver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
2015N232375_03 CONFIDENTIA L
201810
87Phase III-IVliver chemistry stoppi[INVESTIGATOR_90566] -Liver Stoppi[INVESTIGATOR_53053]-absolute ALT 8xULN
ALT Increase ALT 5xULN but <8xULN  persists for 2 weeks
ALT 3xULN but < 5xULN  persists for 4 weeks
Bilirubin1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks
ALT 3xULN but < 5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT  3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the e vent also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with 
study treatment.
Restart/rechallenge is not  allowed , 
permanently discontinue study treatment and 
subject may continue in the study for any 
protocol specified follow up assessmentsViral hepatitis serology4
Only in those with underlying chronic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen)
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within [ADDRESS_738417]
dose6
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury , or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
2015N232375_03 CONFIDENTIA L
201810
88MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin )andperform
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baselineincluding acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct High-
performance liquid chromatography 
(HPLC )assay (quantifies potential 
acetaminophen contribution to liver injury 
in subjects with definite or likely 
acetaminophen use in the preceding week 
[James , 2009]). NOTE: not required in 
China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography)
and /or liver biopsy to evaluate liver 
disease ; complete Liv er Imaging and/or 
Liver Biopsy CRF forms .
1.Serum biliru bin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, i fserum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2.All events of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andinternational 
normalized ratio (INR) >1.5, if INR measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be 
reported as an SAE (excluding studies of hepatic impairment or cirrhosis) ; INR measurement is not required 
and the threshold va lue stated will not apply to subjects receiving anticoagulants
3.New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersens itivity (such as fever, rash or 
eosinophilia)   
4.Includes : Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unav ailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5.If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6.PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the tim e period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].  
2015N232375_03 CONFIDENTIA L
201810
89Phase II I-IVliver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
ALT 5xULN and <8xULN and
bilirubin <2xULN without symptoms
believed to be related to liver injury or 
hypersensitivity , andwho can be 
monitored weekly for 2weeks.
OR
ALT 3xULN and <5xULN and
bilirubin <2xULN without symptoms
believed to be related to liver injury or 
hypersensitivity , andwho can be 
monitored weekly for 4 weeks.Notify the [COMPANY_004] medical monitor within [ADDRESS_738418] 
safety. 
Subject can continue study treatment 
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If ALT decreases from ALT 5xULN and <8xULN 
to ≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
2015N232375_03 CONFIDENTIA L
[PHONE_11666].4. Appendix 4: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
13.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including a n 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology orclinical chemistry ),  or other 
safet y assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that worsen from baseline, and felt to be clinically  significant in the 
medical and scientific judgement of the investigator.
Exacerbation of a chronic or interm ittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnorm al safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
2015N232375_03 CONFIDENTIA L
201810
91condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
13.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under stud y, 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
2015N232375_03 CONFIDENTIA L
201810
92 This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained a nkle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropr iate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_561901] s listed in the above definition.  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do no t result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin 2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
See Appendix 2 for the required liver chemistry  follow -up instructions
13.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
2015N232375_03 CONFIDENTIA L
201810
93Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous t hrombosis/pulmonary  embolism
Revascularization
13.4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or oth er clinical information.  I n such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the stud y.
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y 
the scale’s developer.
The use of a single question from a multidimensional health sur vey to designate a 
cause -effect relationship to an AE is inappropriate.
2015N232375_03 CONFIDENTIA L
[PHONE_11667].4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Seve re:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey  that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used whe n determining regulatory  
reporting requirements.
2015N232375_03 CONFIDENTIA L
201810
95Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  the investigator will provide [COMPANY_004] 
with a cop y of an y post -mortem findings, including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submi t any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
13.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor.
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes avail able.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collecti on tool (e.g., 
InForm s ystem) will be taken off -line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_561934].
2015N232375_03 CONFIDENTIA L
[PHONE_11668].5. Appendix 5: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential 
(FRP)and Collection of Pregnancy  Information
This list does not apply  to FRP with same sex partners, when this is their preferred and 
usual lifesty le or for subjects who are and will continue to be abstinent from penile -
vaginal intercourse on a long term and persistent basis.
Subjects who are FRP must agree to acceptable contraceptive methods approved in their 
local country , when us ed consistently  and correctly  (i.e., in accordance with the approved 
product label and the instructions of the ph ysician) for the duration of the study  and for [ADDRESS_738419] study drug administration.
Contraceptive subdermal implant 
Intrauterine device or intrauterine s ystem 
Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
Injectable progestogen [ Hatcher , 2011]
Contraceptive vaginal ring [ Hatcher , 2011]
Percutaneous contraceptive patches [ Hatcher , 2011]
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011].  
This is an all inclusive list of those methods that meet the [COMPANY_004] definition of highl y 
effective: having a failure rate of less than 1% per y ear when used consistently  and, 
correctly and, when applicable, in accordance with the product label.  For non -product 
methods (e.g.  male sterility ), the investigator determines what is consistent and correct 
use. The [COMPANY_004] definition is based on the definition provided b y the ICH (ICH, M3 
[R2],2009)
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
Based on the absence of an identified reproductive hazard from preclinical studies, 
absence of a genotoxic potential, and very  low levels of mepolizumab that might be 
present in semen, there is no recognized risk for mepolizumab to affect human sperm or 
the fetus if transferred to a female partner via semen. Therefore, the use of condoms or 
other methods of contraception in the male study  subject is not required.
13.5.1. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
2015N232375_03 CONFIDENTIA L
201810
97Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_738420]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix 4. While the investigator is not obligated to actively  seek 
this information in for mer study  participants, he or she may  learn of an SAE through 
spontaneous reporting.
Any female subject who becomes pregnant while participating
Will discontinue study  medication orbe withdrawn from the study (Section 6.5, 
Section 6.6and Section 6.7).
2015N232375_03 CONFIDENTIA L
[PHONE_11669].6. Appendix 6 : Cardiovascular Screening Questions
At screening each subject should be asked the following:
Unrelated to the s ymptoms y ou experience with y our asthma:
1)Do you have any pain or discomfort (such as pressure) in your chest?
If yes, does this pain/discomfort/pressure go to other areas of your bod y 
such as neck, jaw, throat, or down your arms (including a numbness feeling 
in your arm) when it occurs?
2)When you walk at an ordinary pace on a level surface does this produce chest 
pain? If yes, respond to a and b:
a)Does this chest pain or discomfort occur when you are not doing an y 
activities such as resting in bed or sitting in a chair?  
b)Has this chest pain/discomfort been more frequent or more intense or last 
longer or come on with less exertion lately ?
3)When you walk uphill or hurry does this produce chest pain/discomfort?
4)Do you use or have you been previously prescribed nitroglycerine to relieve 
the discomfort ?
If yes, have you needed to increase the number of pi[INVESTIGATOR_561902] y?
If the subject responds “yes” to any of the above questions a study physician should 
further assess for the presence of undiagnosed or unrecognized angina when 
evaluating Exclusion Criterion 4(see Section 6.2)
2015N232375_03 CONFIDENTIA L
[PHONE_11670].7. Appendix 7: Daily  Asthma Sy mptom Score
Each morning subjects will record an asthma sy mptom score using the following scale:
Daily  Symptom Score:
0 = No s ymptoms during the previ ous 24 -hours.
1 = Sy mptoms for one short period during the previous 24 -hours.
2 = Sy mptoms for two or more short periods during the previous 24 -hours.
3 = Sy mptoms for most of the previous [ADDRESS_738421] my  normal 
daily  activities.
4 = Sy mptoms for most of the previous [ADDRESS_738422] m y normal 
daily  activities.
5 = Sy mptoms so severe that I  could not go to work/school or perform normal 
daily  activities.
2015N232375_03 CONFIDENTIA L
201810
[ZIP_CODE].8. Appendix 8: Anaphy laxis Criteria
Joint NI AID/FAAN Second Sy mposium on Anaphy laxis [Sampson , 2006]. The criteria 
do not make a distinction based on underl ying mechanism. These criteria are summarized 
as follows:
1)Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips -
tongue -uvula), and at least one of the following:
a)Respi[INVESTIGATOR_11310] (e.g., dy spnea, wheeze -bronchospa sm, stridor, 
reduced PEF, h ypoxemia) 
b)Reduced blood pressure ( BP)or associated s ymptoms of end -organ 
dysfunction (e.g., hy potonia [collapse], sy ncope, incontinence)
2)Two or more of the following that occur rapi[INVESTIGATOR_11312] a likel y allergen 
for that patient (minutes to several hours):
a)Involvement of the skin -mucosal tissue (e.g., generalized hives, itch -flush, 
swollen lips -tongue -uvula)
b)Respi[INVESTIGATOR_11310] (e.g., dy spnea, wheeze -bronchospasm, stridor, 
reduced PEF, h ypoxemia)
c)Reduced BP or asso ciated sy mptoms (e.g., hy potonia [collapse], sy ncope, 
incontinence)
d)Persistent gastrointestinal sy mptoms (e.g., crampy abdominal pain, vomiting)
3)Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
a)Infants and children: low sy stolic BP (age specific) or greater than 30% 
decrease in s ystolic BP
b)Adults: sy stolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline
2015N232375_03 CONFIDENTIA L
201810
[ZIP_CODE].9. Appendix 9: Country  Specific Requirements
No country -specific requirements exist.
2015N232375_03 CONFIDENTIA L
201810
[ZIP_CODE].10. Appendix 10: Protocol A mendment Changes
13.10.1. Amendment 01 (06-Nov-2015) from the Original Protocol (23 -Jun-
2015 )
Scope: this applies to all sites
Protocol Changes specified in Amendment No. 01 are summarised below:
Change 1: Updated Medical Monitor/SAE Contact I nformation:
Original Text:
Role Name [CONTACT_417536] -hours 
Phone/Cell/
Pager NumberFax 
NumberSite Address
Primary 
Medical 
Monitor  
 
 
MD, 
MFPMNot Applicable Stockley Park 
West
1-[ADDRESS_738423]  
information Medical 
monitor 
as 
above
[COMPANY_003]
[COMPANY_003]
PP
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N232375_03 CONFIDENTIA L
201810
103Revised Text:  
Role Name [CONTACT_132025] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite 
Address
Primary 
Medical 
Monitor  
 MD, 
MFPMNot 
Applicable 
 Stockley 
Park 
West
1-[ADDRESS_738424]  
information Medical 
monitor as 
above
Change 2: Protocol Summary , Overall Design paragraph 1. Simplification of continuous 
treatment.
Original Text:
This is a 52- week, 2 -arm, randomized, double -blind, parallel -group, multi -center study  
evaluating mepolizumab 100 mg and placebo administered subcutaneousl y (SC) every  [ADDRESS_738425] no more than 2 
consecut ive missed doses of mepolizumab treatment [no treatment gaps of more than 12 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N232375_03 CONFIDENTIA L
201810
104weeks (84 day s) between any  two doses while treated with mepolizumab in MEA115666 
or 201312] will be eligible to participate in this study . It is intended that the Follow 
up/Exit Visit or Early  Withdrawal (EW) Visit for studies MEA115666 and 201312 will 
serve as the Pre -Screening/Screening Visit (Visit 0/Visit 1) for this study .
Revised Text:
This is a 52 -week, 2 -arm, randomized, double -blind, parallel -group, multi -center study  
evaluating mepolizumab 100 mg and placebo administered subcutaneousl y (SC) every  [ADDRESS_738426] 
no treatment gaps of more than 12 weeks (84 day s) between any  two doses of 
mepolizumab in MEA115666 or 201312 , will be eligible to participate in this study . 
It is intended that the Follow up/Exit Visit or Early  Withdrawal (EW) Visit for studies 
MEA115666 and 201312 will serve as the Pre -Screening/Screening Visit (Visit 0/Visit 1) 
for this study .
Change 3:Study  Design, Part D: Optional Switch to Open -Label Mepolizumab , last 
paragraph : clarification to process of subject moving from Part C to Part D.
Original Text:
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . 
Revised Text:
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . If a subject discontinues double blind study  
treatment during Part C and does not switch to Part D at their next visit (I P 
Discontinua tion Visit) after experiencing a clinically  significant asthma exacerbation, the 
subject cannot enter Part D at a later visit.  
Change 4: Simplification to definition of “continuous mepolizumab treatment”. Section 
5.1 Overall Design.
Original Text:
This is a [ADDRESS_738427] 6 months of continuous 
treatment with mepolizumab prior to Visit 1 will be eligible to participate in this study .
Continuous mepolizumab treatment: Continuous treatment with mepolizumab is defined 
as no more than 2 consecutive missed doses [no treatment gaps of more than 12 weeks 
(84 day s) between any  two doses]. To calculate the duration of continuous mepolizumab 
2015N232375_03 CONFIDENTIA L
[ADDRESS_738428] the start of treatment in studies MEA115666 
and 201312, and may  include continuous mepolizumab treatment from the following 
prior studies: MEA115661, MEA115588, MEA115575.    
Revised Text:
This is a [ADDRESS_738429] 3 y ears.
Definition of Continuous Mepolizumab Treatment 
Continuous treatment with mepolizumab is defined as no more than 2 consecutive missed 
doses, i.e. no treatment gaps of more than 12 weeks (84 day s) between an y two doses . 
When deriving the period of continuous mepolizumab exposure, treatment from the 
following studies may  be considered: MEA115666, MEA115588, MEA115575, 
MEA115661 and 201312. The earliest date of initiating mepolizumab treatment may  be 
considered when deri ving this total exposure, however if a gap of > 84 days between an y 
two doses of mepolizumab is experienced, this exposure period can no longer be 
considered ‘continuous’. If such an instance occurs the subject's period of continuous 
mepolizumab treatment will be derived from the first dose of mepolizumab following this 
gap in mepolizumab treatment. 
However, if a subject has experienced a gap of >12 weeks (84 day s) between any  two 
doses of mepolizumab within studies MEA115666 or [ADDRESS_738430] from entry  into 201810.
Change 5: To clarify  that the controller medication from Part B and Part C should not be 
altered. Section 5.1 Overall Design
Original Text:
Any increase in controller therapy  in Part B and Part C (except for OCS use for th e 
treatment of exacerbations) should be discussed with the medical monitor.
Revised Text:
Any change in controller regimen or dose in Part B and Part C (except for OCS use for 
the treatment of exacerbations) should be discussed with the medical monitor. 
Change 6: To clarify  the process of a subject switching from Part C to Part D. Section 
5.1 Overall Design: Part D: Optional Switch to Open -Label Mepolizumab .
Original Text:
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . 
2015N232375_03 CONFIDENTIA L
201810
106Revised Text:
Subje cts who permanently discontinue study  treatment in Part C or D of the study  are 
NOT required to withdraw from the study . If a subject discontinues double blind study  
treatment during Part C and does not switch to Part D at their next visit (I P 
Discontinuation Visit) after experiencing a clinically  significant asthma exacerbation, the 
subject cannot enter Part D at a later visit.  
Change 7: Entry  Criterion No. 2, Section 6.[ADDRESS_738431] 
simplification of continuous mepolizumab treatment.
Original Text:
2.MEA115666 or 201312 Study Participation: Participation (through the Follow 
Up/Exit Visit or Early  Withdrawal) in either stud y with documented evidence of 
at least 6 mon ths of continous mepolizumab treatment prior to Visit 1. See 
Section 5.1for the definition of continuous mepolizumab treatment.
Revised Text:
2.Continuous Mepolizumab Treatment during MEA115666 or 201312:
Participation through the Follow Up/Exit Visit or E arly Withdrawal Visit and 
documented evidence of treatment with mepolizumab with no treatment gaps of 
more than 12 weeks (84 day s) between any  two doses within MEA115666 or 
201312.  (A treatment gap of more than 12 weeks [84 day s]cannot occur 
between the end of MEA115666 or 201312 and Visit 1).
Change 8: Added a reference to Section 5.1 in Section 6.3.1 Randomization I nclusion 
Criteria.
Original Text: 
1.Continuous Mepolizumab Treatment: Documented evidence of at least 3years
(156weeks) of treatment with mepolizumab with no treatment gaps of more than 
12 weeks (84 day s) between an y two doses while treated with mepolizumab. 
Revised Text:
1.Continuous Mepolizumab Treatment: Documented evidence of at least 3years
(156weeks) of treatm ent with mepolizumab with no treatment gaps of more than 
12 weeks (84 day s) between an y two doses while treated with mepolizumab. See 
Section 5.1for the definition of continuous mepolizumab treatment.
Change 9: Removal of the Urinal ysis test as it is not required within the mepolizumab 
programme in Section 6.5.Study  Withdrawal Prior to Randomization: Withdrawal during 
Part A or Part B
2015N232375_03 CONFIDENTIA L
201810
107Original Text:
3.Laboratory abnormality: Evidence of clinicall y significant abnormality  in the 
haematological, biochemical o r urinal ysis screen, which in the opi[INVESTIGATOR_561903].
Revised Text:
3.Laboratory abnormality: Evidence of clinicall y significant abnormality  in the 
haematological orbiochemical  scre en, which in the opi[INVESTIGATOR_561904] .
Change 10: Removal of a withdrawal criterion number [ADDRESS_738432] (I P) during Part C or Part D
Rem oved Text:
4.Study treatment unblinded : Unblinding of the study  treatment assigned to a subject 
in Part C.
Unblinded subjects may  switch to open label Part D, per Investigators discrection.
Change 11: Updated section 7.3 Blinding.
Original Text:  
Subjects will be discontinued from study  treatment if the treatment code is unblinded 
by [CONTACT_509456]. Unblinded subjects may  switch to open 
label Part D, per Investigators discrection (Section 6.6) .
Revised Text:
If the treatment code assigned to a subject in Part C is unblinded tothe subject,
Investigator and/or the treating ph ysician /blinded member of site staff , please consult 
the Study  Reference Manual and [COMPANY_004] for guidance. Remediation will be assessed on 
a case b y case basis to mi nimise the impact of an y possible bias.
Change 12: Section 7.9.[ADDRESS_738433] Change 5.
Original Text:
During the fixed open -label period (Part B) and the double -blind treatment period (Part 
C), subjects should maintain the stable dose and regimen of controller therapy established 
in Part A or in studies MEA115666 and 201312 .Any increase in controller therapy  in 
Part B and Part C (except for OCS use for the treatment of exacerbations) should be 
discussed with the medical monitor. 
2015N232375_03 CONFIDENTIA L
201810
108Revised Text:
During the fixed open -label period (Part B) and the double -blind treatment period (Part 
C), subjects should maintain the stable dose and regimen of controller therapy established 
in Part A or in studies MEA115666 and 201312 .Any change in controller regimen or 
dose in Part B and Part C (except for OCS use for the treatment of exacerbations) should 
be discussed with the medical monitor. 
2015N232375_03 CONFIDENTIA L
201810
109Change 13 : The Time and Event table, Table 5, Table 6, Table 7 and Table 8 in Section 8.1 Time and Event Tables, corrected.
Original Section:
Section 8.1 Time and Events Tables
Table 5 Time and Events Table: Screening/Variable Open -Label Run -In Weeks 0 -52 -Part A
PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW9
[ADDRESS_738434]
injection
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Written Informed Consent X
Demography X
Medical History X
Assess cardiac risk factors X
Smoking status X
Inclusion/Exclusion Criteria X
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X X X
Physical Examination X3 X X
Vital Signs X3 X X X X X X X X X X X X X X
12-lead ECG X4 X X X
Adverse Events X5 X X X X X X X X X X X X X X X
Laboratory Assessments6
Haematology X3 X X X
Chemistry (incl. LFT) X3 X X X
Urinalysis X3 X X X
Pregn ancy Test7 U3 U U U U U U U U U U U U U X
Immun ogenicity X3 X X
2015N232375_03 CONFIDENTIA L
201810
110PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW9
[ADDRESS_738435]
injection
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
HbsAg and hepatitis C 
antibody8X
Efficacy Assessments
Exacerbation review X5 X X X X X X X X X X X X X X X
Asthma Control 
Questionnaire -5X3 X X X X X
Spi[INVESTIGATOR_038] X3 X X X
Worksheets /Diary /IP/eCRF
Administer open -label 
mepolizumab6X X X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X X
1. The Pre -Screen Visit and Screening Visit may occur on the same day.
2. Visits should be conducted every [ADDRESS_738436] has reached 3 years of mepolizumab exposure. 
3. As assessed from the Follow Up/Exit Visit or EW from studies MEA115666 or 201312, if Screening for 201810 is conducted on the SAME day. If the MEA11566 6 or 201312 Exit Visit/EW and 201810 
Screening Visit are conducted on different days (no more than 84 days apart), the Physical Exam, Immunogenicity assessment, a nd Spi[INVESTIGATOR_561905]. Other 
assessments should be conducted a t the Screening Visit.
4. Screening ECG must be conducted with ECG equipment for study 201810.
5. Any SAEs and exacerbations related to study participation should be recorded from the time of consent.
6. All laboratory assessments to be completed prior to dosing
7. Urine pregnancy tests (U) should be conducted every [ADDRESS_738437] for the protocol 
unless serum testing is required by [CONTACT_561935] s committee.
8. Hepatitis B Surface Antigen and Hepatitis C antibody ( if Hepatitis C antibody positive, a hepatitis C confirmatory test shou ld be automatically performed to confirm the result. Test should be repeated 
as necessary if clinically indicated)
9. EW = Early Withdrawal. Should be conducted 4 ± [ADDRESS_738438] dose
2015N232375_03 CONFIDENTIA L
201810
111Table 6 Time and Events Table: Screening/Variable Open -Label Run -In Weeks 56 -132-Part A
PART A
ProceduresVariable Open -Label Treatment  Part A1
(window is 1 week)EW44 
weeks
post 
last 
injection
Visit A14/A27 A15/A28 A16/A29 A17/A30 A18/A31 A19/A32 A20/A33 A21 A22 A23 A24 A25 A26
Week of Variable Run -In 56/108 60/112 64/116 68/120 72/124 76/128 80/132 84 88 92 96 100 104
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X
Laboratory Assessments2
Haematology X X X
Chemistry (incl. LFT) X X X
Urinalysis X X X
Pregnancy Test3 U U U U U U U U U U U U U X
Immunogenicity X X
Efficacy Assessments
Exacerbation review X X X X X X X X X X X X X X
Asthma Control Questionnaire -5 X X X X X
Spi[INVESTIGATOR_038] X X X
Worksheets/Diary/IP/eCRF
Administer open -label mepolizumab2 X X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
[PHONE_11671]. Visits should be conducted every [ADDRESS_738439] has reached 3 years of mepolizumab exposure. 
2. All laboratory assessments to be completed prior to dosing
3. Urine pregnancy tests (U) should be conducted every [ADDRESS_738440] 
for the protocol unless serum testing is required by [CONTACT_561936].
4. EW=Early Withdrawal. Should be conducted 4 ± [ADDRESS_738441] dose. 
2015N232375_03 CONFIDENTIA L
201810
113Table 7 Time and Events Table: Fixed Run -In & Double -Blind Treatment Period –Parts B and C
PARTS B&C
ProceduresFixed
Run-in
Part BRandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW2
[ADDRESS_738442]
injection
VisitB1 B21 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 ± 
1-4 ± 11 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Smoking status X
Randomization Criteria X
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X X X X
Physical Examination X X X
Vital Signs X X X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X X X
Laboratory 
Assessments3
Haematology X X X X X X X X X X X X X X X X
Chemistry (incl. LFT) X X X X X
Biomarkers X X X X X X X X X
Urinalysis X X X X X
Pregnancy Test [ADDRESS_738443]/Clinician Global 
Impression RatingX X X X X X
Subject/Clinician Rating of 
Response to TherapyX X X X X
SGRQ X X X X X X
Exacerbation review X X X X X X X X X X X X X X X X X 
2015N232375_03 CONFIDENTIA L
201810
114PARTS B&C
ProceduresFixed
Run-in
Part BRandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW2
[ADDRESS_738444]
injection
VisitB1 B21 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 ± 
1-4 ± 11 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Spi[INVESTIGATOR_038] (pre -and post -
albuterol/salbutamol)X X X X X X
Healthcare resource 
utilizationX X X X X X X X X X X X X X
Review eDiary5 (symptoms, 
rescue use, nocturnal 
awakenings, PEF, ACQ -5, 
missed days of 
work/school)
Worksheets /Diary /IP/
eCRF
Administer open -label 
mepolizumab4X X
Administer double blind 
study treatment3X6 X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X X
Collect 
albuterol/salbutamolX X X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X X
Dispense  eDiary X
Collect eDiary X X7
Collect/review paper diary X X X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X X X
1. Visit B2 is only intended for subjects who experience an exacerbation in the run-in Part B which is not resolved within 7 days of Visit C1 or subjects who fail eDiary Compliance 
Criteria (Section 6.3). These subjects may extend their run -in Part B by 4 weeks and complete Visit B2. All other eligible subjects should proceed directly to Visit C1 following Visit 
B1. B2 will be scheduled 4 ± 1 week after B1, and 4 ± 1 week prior to C1.
2015N232375_03 CONFIDENTIA L
[PHONE_11672]. IPDISC = Discontinuation of IP Visit (only applies to subject s in Part C). EW = Early Withdrawal. Either visit should be conducted 4 ± [ADDRESS_738445] dose.
3. All laboratory assessments to be completed prior to dosing .
4. Urine pregnancy tests (U) should be conducted every [ADDRESS_738446] will be dispensed after Randomization at Visit C1.
7. The eDiary is only collected at an Early Withdrawal visit.
2015N232375_03 CONFIDENTIA L
201810
116Table 8 Time and Events Table: Optional Open -Label Switch to Mepolizumab –Part D
PART D
ProceduresOPTIONAL Open -Label Switch to mepolizumab Part D1
(window is 1 week) IPDISC/EW
[ADDRESS_738447]
injection3 Visit D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13Exit 
Visit
Week of Study2 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X X
Laboratory Assessments4
Haematology5 X X X X X
Chemistry (incl. LFT) X X X
Urinalysis X X X
Pregnancy Test 6 U U U U U U U U U U U U U U U
Immunogenicity X X
Efficacy Assessments
Exacerbation review X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] X X X X X
Worksheets /Diary /IP/eCRF
Administer open -label 
mepolizumab4X X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Review eDiary  
(symptoms, rescue use, 
nocturnal awakenings, PEF, 
ACQ -5, missed days of 
work/school)7X X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
201810
117PART D
ProceduresOPTIONAL Open -Label Switch to mepolizumab Part D1
(window is 1 week) IPDISC/EW
[ADDRESS_738448]/review paper diary X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X
1. The combined treatment period (Part C) and any switch to open -label mepolizumab (Part D) should not exceed a total duration of 52 weeks.
2. Subjects may enter the Open -label Switch Part D at any point during Part C provided they meet switch criteria, starting with the week of study that the s witch is made and 
continuing until week 52, discontinuation of IP or early withdrawal. 
3. IPDISC = Discon tinuation of IP Visit. EW = Early Withdrawal. Either visit should be conducted 4 ± [ADDRESS_738449]’s first 3 visi ts of Part D, and then according to designated Visits in Table 8
6. Urine pregnancy tests (U) should be conducted every [ADDRESS_738450] 
for the protocol unless serum testing is required by [CONTACT_132007].
7. The eDiary should be reviewed at each visit. Weekly review is not required in Part D.
8. The eDiary is only collected at an Early Withdrawal visit.
2015N232375_03 CONFIDENTIA L
201810
118Revised Section:
Section 8 .1 Time and Events Tables
Table 5 Time and Events Table: Screening/Variable Open -Label Run -In Weeks 0 -52 -Part A
PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Written Informed Consent X
Demography X
Medical History X
Assess cardiac risk factors X
Smoking status X
Inclusion/Exclusion Criteria X
Safety Assessments3
Concomitant Medication X X X X X X X X X X X X X X X X
Physical Examination X X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology X X X X
Chemistry (incl. LFT) X X X X
Pregnancy Test4 U U U U U U U U U U U U U U U
Immun ogenicity X X X
HbsAg and hepatitis C 
antibody X
Efficacy Assessments3
Exacerbation review X5 X X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
201810
119PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Asthma Control 
Questionnaire -5X X X X X X
Spi[INVESTIGATOR_038] X X X X
Worksheets /Diary /IP/eCRF
Administer open -label 
mepolizumabX X X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X X
1. The Pre -Screen Visit and Screening Visit may occur on the same day.
2. Visits should be conducted every [ADDRESS_738451] has reached 3 years of mepolizumab exposure. 
3. Please see the SRM for details on which screening procedures to perform for subjects entering from 201312 and MEA115666.  ALL procedures should be completed prior to 
dosing with open -label mepolizumab.
4. Urine pregnancy tests (U) should be conducted for women of child bearing potential. 
5. EW = Early Withdrawal. Should be conducted 4 ± [ADDRESS_738452]’s last dose
2015N232375_03 CONFIDENTIA L
201810
120Table 6 Time and Eve nts Table: Screening/Variable Open -Label Run -In Weeks 56 -132-Part A
PART A
ProceduresVariable Open -Label Treatment  Part A1
(window is 1 week)EW
Visit3
Visit A14/A27 A15/A28 A16/A29 A17/A30 A18/A31 A19/A32 A20/A33 A21 A22 A23 A24 A25 A26
Week of Variable Run -In 56/108 60/112 64/116 68/120 72/124 76/128 80/132 84 88 92 96 100 104
Safety Assessments
Concomitant Medication X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X
Laboratory Assessments
Haematology X X X
Chemistry (incl. LFT) X X X
Pregnancy Test2 U U U U U U U U U U U U U X
Immunogenicity X X
Efficacy Assessments
Exacerbation review X X X X X X X X X X X X X X
Asthma Control Questionnaire -5 X X X X X
Spi[INVESTIGATOR_038] X X X
Worksheets/Diary/IP/eCRF
Administer open -label mepolizumab X X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X
1. Visits should be conducted every [ADDRESS_738453] has reached 3 years of mepolizumab exposure. 
2. Urine pregnancy tests (U) should be conducted for women of child bearing potential. 
3. EW = Early Withdrawal. Should be conducted 4 ± [ADDRESS_738454]’s last dose
2015N232375_03 CONFIDENTIA L
201810
121Table 7 Time and Events Table: Fixed Run -In & Double -Blind Treatment Period –Parts B and C
PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
Smoking status X
Randomization Criteria X
Safety Assessments2
Concomitant 
MedicationX X X X X X X X X X X X X X X X X X
Physical Examination X X X X
Vital Signs X X X X X X X X X X X X X X X X X X
12-lead ECG X X X X X
Adverse Events X X X X X X X X X X X X X X X X X X
Laboratory 
Assessments2
Haematology X X X X X X X X X X X X X X X X X
Chemistry (incl. LFT) X X X X X X
Biomarkers X X X X X X X X X
Pregnancy Test [ADDRESS_738455]/Clinician 
Global Impression 
RatingX X X X X X
Subject/Clinician 
Rating of Response to 
TherapyX X X X X
2015N232375_03 CONFIDENTIA L
201810
122PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
SGRQ X X X X X X
Exacerbation review X X X X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] (pre -and 
post-
albuterol/salbutamol)X8 X X X X X X
Healthcare resource 
utilizationX X X X X X X X X X X X X X
Review eDiary4
(symptoms, rescue 
use, nocturnal 
awakenings, PEF, 
ACQ -5, missed days of 
work/school)
Worksheets /Diary /IP/
eCRF2
Administer open -label 
mepolizumab4X X
Administer double 
blind study treatmentX5 X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X X
Collect 
albuterol/salbutamolX X X X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X X
Dispense  eDiary X
Collect eDiary X X X6
2015N232375_03 CONFIDENTIA L
201810
123PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
[ADDRESS_738456]/review paper 
diaryX X X X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X X X X
1. Visit B2 is only intended for subjects who experience an exacerbation in the run-in Part B which is not resolved within 7 days of Visit C1 or subjects who fail eDiary Compliance 
Criteria (Section 6.3). 
2. All assessments to be completed prior to dosing .
3. Urine pregnancy tests (U) should be conducted every [ADDRESS_738457] will be dispensed after Randomization at Visit C1.
6. The eDiary is only collected at an Early Withdrawal visit and not at IPDISC in Part C.
7. IPDISC/EW visit should be conducted 4 ± [ADDRESS_738458]’ s last dose
8. Only pre-bronchodilator spi[INVESTIGATOR_561886].
2015N232375_03 CONFIDENTIA L
201810
124Table 8 Time and Events Table: Optional Open -Label Switch to Mepolizumab –Part D
PART D
ProceduresOPTIONAL Open -Label Switch to mepolizumab Part D1
(window is 1 week)
IPDISC/EW 
Visit8
Visit D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13Exit 
Visit
Week of Study2 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Safety Assessments3
Concomitant Medication X X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology4 X X X X X
Chemistry (incl. LFT) X X X
Pregnancy Test 5 U U U U U U U U U U U U U U U
Immunogenicity X X
Efficacy Assessments3
Exacerbation review X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] X X X X X
Worksheets /Diary /IP/eCRF3
Administer open -label 
mepolizumabX X X X X X X X X X X X X
Dispense albuterol/salbutamol X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X
Review eDiary6  
(symptoms, rescue use, 
nocturnal awakenings, PEF, 
ACQ -5, missed days of 
work/school)X X X X X X X X X X X X X X X
Collect eDiary X X7
2015N232375_03 CONFIDENTIA L
201810
125PART D
ProceduresOPTIONAL Open -Label Switch to mepolizumab Part D1
(window is 1 week)
IPDISC/EW 
Visit8
Visit D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13Exit 
Visit
Week of Study2 [ADDRESS_738459]/review paper diary X X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X
1. The combined treatment period (Part C) and any switch to open -label mepolizumab (Part D) should not exceed a total duration of [ADDRESS_738460]’s first 3 visits of Part D, and then according to designated Vi sits in Table 8
5. Urine pregnancy tests (U) should be conducted every 4 weeks for women of child bea ring potential.
6. The eDiary should be reviewed at each visit. Weekly review is not required in Part D.
7. The eDiary is only collected at an Early Withdrawal or Exit visit.
8. IPDISC/EW visit should be conducted 4 ± [ADDRESS_738461]’s last dose
2015N232375_02 CONFIDENTIA L
201810
126Change 14: Section 8.[ADDRESS_738462] 
changes made throughout protocol and specifically in the Tine and Event Tables.
Original T ext:
8.2. Screening and Critical Baseline Assessments
Informed consent/assent will be obtained at the Pre -screen Visit or Screening Visit (if 
Pre-screen and Screening Visits are performed on the same day ).
8.2.1. Critical procedures performed at Screening (Visit 1)
If the MEA115666 or 201312 Exit Visit/EW and 201810 Screening Visit are conducted 
on different day s (no more than 84 day s apart), the Phy sical Exam, I mmunogenicity  
assessment, and Spi[INVESTIGATOR_561887]. Other assessme nts 
should be conducted at the Screening Visit.
Review Inclusion/Exclusion criteria (see Section 6)
Demographic information including gender, ethnic origin, race, year of birth
Medical history  including smoking status, history of sinusitis, nasal 
polyposis , aspi[INVESTIGATOR_270861], duration of asthma, courses of rescue 
corticosteroids, history  of previous intubations, asthma exacerbation history  
in previous y ear, asthma triggers
Vital signs 
Physical exam  (conducted at the Exit/EW Visit from study  MEA115666 or 
201312) 
Resting 12 lead ECG  (using 201810 equipment)
Therap y history  (review concomitant medications from the previous [ADDRESS_738463] dose of study  medication)
Cardiovasc ular medical history /risk factors (as detailed in the eCRF) will be 
assessed at screening. This assessment must include a review of the subject 
responses to the cardiovascular assessment questions (see Appendix 6) 
Exacerbation review 
Smoking status
Asthm a Control Questionnaire (ACQ -5)
Spi[INVESTIGATOR_038]  (conducted at the Exit/EW Visit from study  MEA115666 or 
201312)
Laboratory  tests:
Chemistry  (including liver function test [LFT])
Haematology  with differential
Urinaly sis
2015N232375_02 CONFIDENTIA L
201810
127Immunogenicit y  (conducted at the Exit/EW Visit from study 
MEA115666 or 201312) 
Hepatitis B Surface Antigen and hepatitis C antibody
Urine pregnancy  test-for all females of child bearing potential (Follicle 
Stimulating Hormone [FSH] will be assessed to confirm child -bearing 
status, if clinically indicated)
AE/SAE assessment 
8.2.2. Critical procedures performed at entry  to Part B (Visit B1)
Vital signs
Resting 12 -lead ECG
Physical examination
Concomitant medication review
Exacerbation review
Laboratory  tests:
Chemistry  (including LFT)  
Haematology  with differential
Urinaly sis
Urine pregnancy  test-for all females of child bearing potential
AE/SAE assessment
8.2.3. Critical procedures performed at Randomization (Visit C1)
Review of randomization criteria (see Section 6.3)
Subject/Clinicia n global impression of asthma severity rating
Subject/Clinician rating of response to therap y 
St. George’s Respi[INVESTIGATOR_21606] (SGRQ)
Vital signs
Spi[INVESTIGATOR_038]  (pre-and post -albuterol/salbutamol)
Review/Collect eDiary  data 
Exacerbation review
Smoking status
Concomitant medication assessment 
Laboratory  tests:
Clinical Chemistry  (including LFT)
Haematology  with differential
2015N232375_02 CONFIDENTIA L
201810
128Biomarker sample
Urinaly sis
Urine pregnancy  test for all females of childbearing potential
AE/SAE assessment
Revised Text:
8.2. Screening and Critical Baseline Assessments
Informed consent/assent will be obtained at the Pre -screen Visit or Screening Visit (if 
Pre-screen and Screening Visits are performed on the same day ).
8.2.1. Critical procedures performed at Screening (Visit 1)
If the MEA115666 or 201312 Exit Visit/EW and 201810 Screening Visit are conducted 
on different day s (no more than 84 day s apart), the Phy sical Exam, I mmunogenicity  
assessment, and Spi[INVESTIGATOR_561887]. Other assessments 
should be conducted at the Screening Visit.  Please see the Study  Reference Manual 
(SRM) for full details.
Review Inclusion/Exclusion criteria (see Section 6)
Demographic information including gender, ethnic origin, race, year of birth
Medical history  including smoking status, history of sinusitis, nasal 
polyposis, aspi[INVESTIGATOR_270861],  courses of rescue corticosteroids, 
Vital signs 
Physical exam  
Resting 12 lead ECG  
Therap y history  (review concomitant medications from the previous [ADDRESS_738464] do se of study  medication)
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be 
assessed at screening. This assessment must include a review of the subject 
responses to the cardiovascular assessment questions (see Appendix 6) 
Exacerb ation review 
Smoking status
Asthma Control Questionnaire (ACQ -5)
Spi[INVESTIGATOR_038]  
Laboratory  tests:
Chemistry  (including liver function test [LFT])
Haematology  with differential
Immunogenicit y  
Hepatitis B Surface Antigen and hepatitis C antibody
2015N232375_02 CONFIDENTIA L
201810
129Urine pregna ncy test-for all females of child bearing potential (Follicle 
Stimulating Hormone [FSH] will be assessed to confirm child -bearing 
status, if clinically  indicated)
AE/SAE assessment 
8.2.2. Critical procedures performed at entry  to Part B (Visit B1)
Vital signs
Resting 12 -lead ECG
Physical examination
Concomitant medication review
Exacerbation review
Laboratory  tests:
Chemistry  (including LFT)  
Haematology  with differential
Urine pregnancy  test-for all females of child bearing potential
AE/SAE assessment
8.2.3. Critical procedures performed at Randomization (Visit C1)
History  of previous intubations, asthma exacerbation history  in previous year, 
asthma triggers
Review of randomization criteria (see Section 6.3)
Subject/Clinician global impression of asthm a severity  rating
St. George’s Respi[INVESTIGATOR_21606] (SGRQ)
Vital signs
Spi[INVESTIGATOR_038]  (pre-and post -albuterol/salbutamol)
Review/Collect eDiary  data 
Exacerbation review
Smoking status
Concomitant medication assessment 
Laboratory  tests:
Clinical Chemistry  (including LFT)
Haematology  with differential
Biomarker sample
Urine pregnancy  test for all females of childbearing potential
AE/SAE assessment
2015N232375_02 CONFIDENTIA L
201810
130Change 14 : Removal of text in Section 8.4.5 Electrocardiogram (ECG)
Original Text:
8.4.5. Electrocardi ogram (ECG)
Twelve -lead ECGs will be obtained at each time point specified in the Time and 
Events Schedule s(Table 5, Table 6, Table 7and Table 8), using the equipment 
provided for Stud y 201810 . 
Revised Text:
8.4.5. Electrocardiogram (ECG)
Twelve -lead E CGs will be obtained at each time point specified in the Time and 
Events Schedule s(Table 5, Table 6, Table 7and Table 8).
Change 15: Removal of Urinaly sis from Section 8.4.[ADDRESS_738465] updated footnotes in Time and Event tables.
Original Text: 
All protocol required laboratory  assessments (haematology , clinical chemistry  and 
urinaly sis) must be conducted in accordance with the Laboratory  Manual , and Protocol 
Time and Events S chedule (Table 5, Table 6, Table 7 and Table 8) ..
Revised Text:
All protocol required laboratory  assessments (haematology andclinical chemistry ) must 
be conducted in accordance with the Laboratory  Manual , and Protocol Time and Events 
Schedule (Table 5, Ta ble 6, Table 7 and Table 8) .
Original Text:
Haematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 9 .
Table 9 Protocol Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatase Albumin
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
2015N232375_02 CONFIDENTIA L
201810
131Laboratory 
AssessmentsParameters
Other 
Screening 
TestsHepatitis B (HBsAg)
Hepatitis C (Hep C antibody )
FSH and estradiol (if clinically  indicated, in women of non -child 
bearing potential onl y)
Alcohol and drug screen (if clinically  indicated, to include at 
minimum: amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], 
cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (for women of child bearing potential) 2
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_561906] g iven in Appendix [ADDRESS_738466] for the protocol unless serum testing is required 
by [CONTACT_132007].
Revised Text:
Haematology , clinical chemistry and additional parameters to be tested are listed in Table 
9.
Table 9 Protocol Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline p hosphata se Albumin
Other 
Screening 
TestsHepatitis B (HBsAg)
Hepatitis C (Hep C antibody )2
FSH and estradiol ( if clinically  indicated, in women of non -child 
bearing potential onl y)
Alcohol and drug screen ( if clinically  indicated, to include at 
minimum: amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], 
2015N232375_02 CONFIDENTIA L
201810
132Laboratory 
AssessmentsParameters
cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Urine hCG Pregnancy  test (for women of child bearing potential) 3
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_97177] [ADDRESS_738467] for the protoco l unless serum testing is required 
by [CONTACT_132007].
Change 15: Removal of urinaly sis from Section 13.4.1 Definition of an AE.
Original Text:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
orother safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Revised Text:
Any abnormal l aboratory test results (hematology orclinical chemistry ) or other 
safet y assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that worsen from baseline, and felt to be clinically  significant in the 
medical and scientific judgement of the investigator.
Change 16: Updated Appendix 13.[ADDRESS_738468] of Highl y Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential (FRP) and Collection of 
Pregnancy  Information
Original Text:
Section 13.5: Appendix 5: Mo dified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) and Collection of Pregnancy 
Information
This list does not apply  to FRP with same sex partners, when this is their preferred and 
usual lifesty le or fo r subjects who are and will continue to be abstinent from penile -
vaginal intercourse on a long term and persistent basis.
Subjects who are FRP must agree to acceptable contraceptive methods approved in their 
local country , when used consistently  and correc tly (i.e., in accordance with the approved 
2015N232375_02 CONFIDENTIA L
[ADDRESS_738469] label and the instructions of the ph ysician) for the duration of the study  and for [ADDRESS_738470] study drug administration.
Contraceptive subdermal implant 
Intrauterine device or intrauterine s ystem 
Oral Contraceptive, either combined or progestogen alone [ Hatcher , 2007a] 
Injectable progestogen [ Hatcher , 2007a]
Contraceptive vaginal ring [ Hatcher , 2007a]
Percutaneous contraceptive patches [ Hatcher , 2007a]
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2007a].  
Male condom plus partner use of one of the contraceptive options below:
oContraceptive subdermal implant 
oIntrauterine device or intrauterine s ystem 
oOral Contraceptive, either combined or progestogen alone [ Hatcher , 
2007a] I njectable progestogen [ Hatcher , 2007a]
oContraceptive vaginal ring [ Hatcher , 2007a]
oPercutaneous contraceptive patches [ Hatcher , 2007a]
This is an all inclusive list of those methods that meet the [COMPANY_004] definition of highl y 
effective: having a failure rate of less than 1% per y ear when used consistently  and, 
correctly  and, when applicable, in accordance with the product label.  For non -produ ct 
methods (e.g.  male sterility ), the investigator determines what is consistent and correct 
use. The [COMPANY_004] definition is based on the definition provided b y the ICH (I CH guideline 
M3(R2) on non -clinical safet y studies for the conduct of human clinical tria ls and 
marketing authorisation for pharmaceuticals, 2009; EMA/CPMP/I CH/286/1995). 
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
Based on the absence of an identified reproductive hazard from preclinical studies, 
absence of a genotoxic potential, and very  low levels of mepolizumab that might be 
present in semen, there is no recognized risk for mepolizumab to affect human sperm or 
the fetus if transferred to a female partner via seme n.Therefore, the use of condoms or 
other methods of contraception in the male study  subject is not required.
Revised Text:
This list does not apply  to FRP with same sex partners, when this is their preferred and 
usual lifesty le or for subjects who are an d will continue to be abstinent from penile -
vaginal intercourse on a long term and persistent basis.
2015N232375_02 CONFIDENTIA L
[ADDRESS_738471] agree to acceptable contraceptive methods approved in their 
local country , when used consistently  and correctly  (i.e., in accorda nce with the approved 
product label and the instructions of the ph ysician) for the duration of the study  and for [ADDRESS_738472] study drug administration.
Contraceptive subdermal implant 
Intrauterine device or intrauterine s ystem 
Combined estrog en and progestogen oral contraceptive [Hatcher, 2011]
Injectable progestogen [ Hatcher , 2011]
Contraceptive vaginal ring [ Hatcher , 2011]
Percutaneous contraceptive patches [ Hatcher , 2011]
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011].  
This is an all inclusive list of those methods that meet the [COMPANY_004] definition of highl y 
effective: having a failure rate of less than 1% per y ear when used consistently  and, 
correctly  and, when applicable, in accordance with the product label.  For non -product 
methods (e.g.  male sterility ), the investigator determines what is consistent and correct 
use. The [COMPANY_004] definition is based on the definiti on provided b y the ICH (ICH, M3 [R2]
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
Based on the absence of an identified reproductive hazard from preclinical studies, 
absence of a genotoxic potential, and very  low levels of mepolizumab that might be 
present in semen, there is no recognized risk for mepolizumab to affect human sperm or 
the fetus if transferred to a female partner via semen. Therefore, the use of condoms or 
other met hods of contraception in the male study  subject is not required.
Change 17: Changed Reference related to change 16 in Section 12 References
Original Text:
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology .19th edition. [LOCATION_001]: Ardent Media, 2007(a): 24. Table 3 -
2.
Revised Text:
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, editors. 
Contraceptive Technology . 20th edition.  Atlanta, Georgia: Ardent Media, Inc., 2011:50. 
Table 3-2.
Change 18: Changed entry  criterion No. 5 in Section 6.3.2 Randomisation Exclusion 
Criteria to allow the result to be communicated to Site Staff if positive.
Original Text: 
2015N232375_02 CONFIDENTIA L
[PHONE_11673].  Immunogenicity: Positive neutralizing antibody  status based on the last sample
obtained .
Revised Text:
5.  Immunogenicity: Positive neutralizing antibody  status based on the last result
obtained .
2015N232375_02 CONFIDENTIA L
201810
[ZIP_CODE].10.2. Amendment 2 ( 07-JUL-2016 ) from the A mendment 1 (06 -NOV -
2015)
Scope: this app lies to all sites
Protocol Changes specified in Amendment No. 02 are summarised below:
Change 1: To amend Section 5.6.1 Risk Assessment .
Original text: 
The majority  of reports of sy stemic non -allergic and allergic (i.e., h ypersensitivity ) 
reactions have been non -serious and resolved without sequelae following minimal 
supportive care. There have been rare reports of serious reactions. To date, there 
have been no reports of severe life -threatening anaphy laxis.
Revised text:
The majority  of reports of sy stem ic non -allergic and allergic (i.e., h ypersensitivity ) 
reactions have been non -serious and resolved without sequelae following minimal 
supportive care. There have been rare reports of serious reactions. 
Change 2 :To correct the numbering of Section 6.2: Exclusion Criteria, which started at 
No. 2. All consequent exclusion criteria also change.
Original Text :
2.MEA115666 or 201312 IP Discontinuation: Subjects withdrawn from I Por 
withdrawn from stud y participation from either MEA115666 or 201312 for safet y 
reasons
Revised text:
1.MEA115666 or 201312 IP Discontinuation: Subjects withdrawn from I Por 
withdrawn from stud y participation from either MEA115666 or 201312 for safet y 
reasons
Change 3:To amend Exclusion crit erion No. 7 in Section 6.2: Exclusion Criteria .
Original t ext:
8.Other Monoclonal Antibodies : Subjects who have received an y monoclonal 
antibody  (other than Xolair) to treat inflammatory disease within 5 half -lives of Visit 
1. 
Revised text:
7.Other Monoclonal Antibodies : Subjects who have received an y monoclonal 
antibody  within 5 half -lives of Visit 1. 
2015N232375_02 CONFIDENTIA L
201810
137Change 4:To amend Randomization Exclusion criterion No. 7 in Section 6. 3.2: 
Randomization Exclusion Criteria.
Original text:
7.Current Asthma Exacerbation: Subjects with an asthma exacerbation that has not 
resolved completel y within 7 days of Visit C1. Subjects who experience an 
exacerbation in the fixed run-in Part B which is not resolved within 7 day s of Visit 
C1may extend their run -in Part B b y 4 weeks.
Revi sed text:
7.Current Asthma Exacerbation: Subjects with an asthma exacerbation (or asthma 
worsening) that has not resolved completel y within 7 days of Visit C1. Subjects who 
experience an exacerbation (or asthma worsening) in the fixed run-in Part B which is 
not resolved within 7 days of Visit C1may extend their run -in Part B b y 4 weeks.
Change 5:Added text to Section 7.[ADDRESS_738473] and Other Study  
Treatments.
Original Text: 
Safety  monitoring of subjects is required during SC administration in accordance with 
standard of care at the site.
Revised text:
Safety  monitoring of subjects is required during SC administration in accordance with 
standard of care at the site. Such monitoring will include general safet y monitori ng 
including monitoring for systemic (i.e., allergic/IgE -mediated and non -allergic) and 
local injection site reac tions. In the event of an acute severe reaction (e.g., 
anaph ylaxis) following administration of study  treatment, there are personnel/staff 
onsite at the treatment facility  who are appropriately  trained in basic life support to 
manage the subject including administration of medications (e.g., epi[INVESTIGATOR_238]), and 
have access to a s ystem that can promptl y transport the patient to another facility for 
additional care if appropriate.
Change 6:To amend Section 7.9.1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .
Original t ext:
Additional asthma medications such as theoph yllines, anti -leukotrienes or Xolair
(omalizumab) will be permitted provided that they have been taken regularly (per label)
in the 12 weeks prior to randomization (Visit C1).
Revised t ext: 
Additional asthma medi cations such as theoph yllines or anti-leukotrienes will be 
permitted provided that they  have been taken regularly (per label )in the 12 weeks prior 
to randomization (Visit C1 ).  If uncertain whether a medication is permitted please 
confirm with the medical monitor.
2015N232375_02 CONFIDENTIA L
201810
138Change 7:Multiple changes to Section 7.9.2 Prohibited Medications and Non -Drug 
Therapi[INVESTIGATOR_014] .
Original text:
The following medications are not allowed prior to screening (Visit 1) according to the 
following schedule, or during the stud y:
Table 11 Medications not allo wed prior to the Screening Visit 1 and throughout 
the study
MedicationWashout Time
Prior to Screening Visit 1
Investigational drugs 1 month or 5 half -lives whichever is 
longer
Other monoclonal antibodies (other than Xolair) 5 half -lives
Experimental anti -inflammatory drugs (non biologicals) 3 months
Immunosuppressive medications such as those listed below (not all inclusive)
Corticosteroids intramuscular, long -acting depot if 
used to treat a condition other than asthma3 months
Methotrexate, troleandomycin, cyclosporin, 
azathioprine 1 month
Oral gold 3 months
Chemotherapy used for conditions other than 
asthma12 months
Regular systemic (oral or parenteral) corticosteroids 
for the treatment of conditions other than asthma3 months
Additionally , Bronchial Thermoplasty  and Radiotherapy  are excluded for 12 months 
prior to Visit 1 and throughout the stud y.  Neither CPAP nor ox ygen therapy may be 
initiated on or after Visit 1.
Recreational drug use is not allowed during the study .
Revised text:
The following medications are not permitted during the 201810 study :
2015N232375_02 CONFIDENTIA L
201810
139Table 12 Medications not permitted during the study
Medication s
Investigational drugs (other than mepolizumab)
Other monoclonal antibodies
Experimental anti -inflammatory drugs
Any medication with a significant immunosupressive effect. (some examples listed below )
Methotrexate, troleandomycin, cyclosporin, azathioprine 
Oral gold
Chemotherapy
Regular systemic (oral or parenteral) corticosteroids for the treatment of conditions other 
than asthma
Long acting depot, intramuscular injections of c orticosteroids if used to treat a condition 
other than asthma
Additionally , Bronchial Thermoplasty  and Radiotherapy  are excluded for [ADDRESS_738474] the medical monitor prior to 
administration to confirm if the medication is proh ibited.
Change 8:Within Table 5,6, [ADDRESS_738475] of re ducing replication, only  
Table 5 is shown below.
2015N232375_03 CONFIDENTIA L
201810
140Original table: 
Table 5           Time and Events Table: Screening/Variable Open -Label Run -In Weeks 0 -52 -Part A
PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Written Informed Consent X
Demography X
Medical History X
Assess cardiac risk factors X
Smoking status X
Inclusion/Exclusion Criteria X
Safety Assessments3
Concomitant Medication X X X X X X X X X X X X X X X X
Physical Examination X X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology X X X X
Chemistry (incl. LFT) X X X X
Pregnancy Test4 U U U U U U U U U U U U U U U
Immun ogenicity X X X
HbsAg and hepatitis C 
antibody X
Efficacy Assessments3
Exacerbation review X X X X X X X X X X X X X X X X
Asthma Control 
Questionnaire -5X X X X X X
Spi[INVESTIGATOR_038] X X X X
Worksheets /Diary /IP/eCRF
2015N232375_03 CONFIDENTIA L
201810
141PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Administer open -label 
mepolizumabX X X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X X
Revised Table:
Table 13 Time and Events Table: Screening/Variable Open -Label Run -In Weeks 0 -52 -Part A
PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Written Informed Consent X
Demography X
Medical History X
Assess cardiac risk factors X
Smoking status X
Inclusion/Exclusion Criteria X
Safety Assessments3
2015N232375_03 CONFIDENTIA L
201810
142PART A
ProceduresPre-
Screen1Exit/EW 
Visit 
MEA115666 
or 201312 /
Screen1Variable Open -Label Treatment  Part A2
(window is 1 week)EW Visit5
Visit 0 1 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13
Week of Variable Run -In 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Concomitant Medication X X X X X X X X X X X X X X X X
Physical Examination X X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X X
Laboratory Assessments3
Haematology X X X X
Chemistry (incl. LFT) X X X X
Pregnancy Test4 U U U U U U U U U U U U U U U
Immun ogenicity X X X
HbsAg and hepatitis C 
antibody X
Efficacy Assessments3
Exacerbation review X X X X X X X X X X X X X X X X
Asthma Control 
Questionnaire -5X X X X X X
Spi[INVESTIGATOR_038] X X X X
Worksheets /Diary /IP/eCRF
Administer open -label 
mepolizumabX X X X X X X X X X X X X X
Dispense 
albuterol/salbutamolX X X X X X X X X X X X X X
Collect albuterol/salbutamol X X X X X X X X X X X X X X
Dispense paper diary X X X X X X X X X X X X X X
Collect/review paper diary X X X X X X X X X X X X X X
Contact [CONTACT_12067] X X
Complete eCRF X X X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
201810
143Change 9:  Adding Ph ysical Examination to Table 7 .
Original Table:
Table 7 Time and Events Table: Fixed Run -In & Double -Blind Treatment Period –Parts B and C
PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
Smoking status X
Randomization Criteria X
Safety Assessments2
Concomitant 
MedicationX X X X X X X X X X X X X X X X X X
Physical Examination X X X X
Vital Signs X X X X X X X X X X X X X X X X X X
12-lead ECG X X X X X
Adverse Events X X X X X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
201810
144Revised Table:
Table 7 Time and Events Table: Fixed Run -In & Double -Blind Treatment Period –Parts B and C
PARTS 
B&C
ProceduresFixed
Run-in
Part BEW from 
Part B7RandomizationDouble -Blind Treatment Part C 
(window is 1 week)IPDISC /EW 
Visit 7
VisitB1 B21 Part B EW C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13Exit 
Visit
Week of S tudy -4 
± 1-4 ± 
110 4 8 12 16 20 24 28 32 36 40 44 48 52
Smoking status X
Randomization Criteria X
Safety Assessments2
Concomitant 
MedicationX X X X X X X X X X X X X X X X X X
Physical Examination X X X X X
Vital Signs X X X X X X X X X X X X X X X X X X
12-lead ECG X X X X X
Adverse Events X X X X X X X X X X X X X X X X X X
2015N232375_03 CONFIDENTIA L
201810
145Change 10:Adding Ph ysical Examination to S ection 8.2.3 
Original text:
8.2.3 Critical procedures performed at Randomization (Visit C1)
History  of previous intubations, asthma exacerbation history  in previous year, 
asthma triggers
Review of randomiz ation criteria (see Section 6.3)
Subject/Clinician global impression of asthma severity  rating
St.George’s Respi[INVESTIGATOR_21606] (SGRQ)
Vital signs
Spi[INVESTIGATOR_038]  (pre-and post -albuterol/salbutamol)
Review /Collect eDiary  data 
Exacerbation review
Smoking status
Concomitant medication assessment Laboratory  tests:
Clinical Chemistry (including LFT)
Haematology  with differential
Biomarker sample
Urine pregnancy  test for all females of childbearing potential
AE/SAE assessment
Revised text:
8.2.3 Critical procedures performed at Randomization (Visit C1)
History  of previous intubations, asthma exacerbation history  in previous year, 
asthma triggers
Review of randomiz ation criteria (see Section 6.3)
Subject/Clinician global impression of asthma severity  rating
St.George’s Respi[INVESTIGATOR_21606] (SGRQ)
Vital signs
Physical examination
Spi[INVESTIGATOR_038]  (pre-and post -albuterol/salbutamol)
Review /Collect eDiary  data 
Exacerbation review
2015N232375_03 CONFIDENTIA L
201810
146Smoking status
Concomitant medication assessment
Laboratory  tests:
Clinical Chemistry (including LFT)
Haematology  with differential
Biomarker sample
Urine pregnancy  test for all females of childbearing potential
AE/SAE assessment
Change 11 : To clarify  how to administer and who should administer the 
Subject/Clinician Rating of Global Impression of Disease Severity  and Response to 
Therap y
Original text:
[IP_ADDRESS] Subject/Clinician Rating of Global Impression of Disease Severity  and 
Response to Therapy
The Global Impressions of Disease Severit y and Response to Therap y should be the first 
procedure completed b y the subject at the specified study  visit. To avoid biasing 
responses, the subjects should not be told the results of diagnostic tests prior to 
completing the questionnaire and should be completed before an y procedures are 
performed on the subject to avoid influencing the subject’s response.
Revised Text:
[IP_ADDRESS] Subject/Clinician Rating of Global Impression of Disea se Severity  and 
Response to Therapy
The Global Impressions of Disease Severit y and Response to Therap y should be the first 
procedure completed b y the subject and clinician (Primary  or Sub I nvestigators) at the 
specified stud y visit. To avoid biasing respon ses, the subjects should not be told the 
results of diagnostic tests prior to completing the questionnaire sand these questionnaires 
should be completed before an y procedures are performed on the subject to avoid 
influencing the subject’s and Investigator’ s response.
Change 12: Clarify ing the risks to blind break when performi ng local laboratory  testing 
in Section 8.4.6 Clinical Safety Laboratory  Assessments
Original text:
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF.
2015N232375_03 CONFIDENTIA L
201810
147Revised text:
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF. Please note that any non -
protocol specified local laboratory  result has the potential to break the blind due to the 
eosinophils result being available.  Please see the Study  Reference Manual for guidance.
Change 1 3: To amend S ection 8.5 Biomarker(s)/Pharmacod ynamic Markers to align it 
with recent standard text.
Original text:
Additionally , a broad spectrum of inflammatory  biomarkers of interest in the blood will
also be considered for examination (e.g., interleukin (IL) -4, IL-5 (total and free), IL13, 
and periostin, IL9, IL25, IL33, YKL -40, osteopontin, C -reactive protein [CRP], 
surfactant protein D [SPD], etc.). All blood will be anal yzed by a central laboratory  or by 
[CONTACT_23983]. The site staff and central study  team will be blinded to each subject’s IL -[ADDRESS_738476] -randomization. Full details regarding sample collection , processing 
and shippi[INVESTIGATOR_561907].
Revised text: 
Blood (serum) samples will be collected during this study  and may  be used for the 
purposes of measuring biomarkers to identify  factors that may  influence the development 
of asthma and/or medically  related conditions, as well as the biologica l and clinical 
responses to mepolizumab. Blood samples for biomarker testing will be stored for up to 
[ADDRESS_738477] the potential to break the blind will be 
blinded to the site staff until the clinical study  report is fina lised.
Full details regarding sample collection, processing and shippi[INVESTIGATOR_561908].   
Change 1 4:Xolair removed from the Trademark Information section.
Original text:
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_561937]
2015N232375_03 CONFIDENTIA L
201810
148Revised text:
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_561933]